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Uterine artery embolisation (UAE), 
new treatment for uterine leiomyomas 
has been developed to substitute for 
major surgery. This randomised study 
comparing UAE and hysterectomy 
confirmed that UAE is a safe and 
effective treatment for symptomatic
leiomyomas. In addition, this thesis 
observed that post-UAE pain is often 
severe and is partly explained by 
myometrial ischaemia on 24-hour 
magnetic resonance imaging (MRI)
and large volume of embolic material. 
MRI measures can also be used to 
predict uterus and leiomyoma size 
reduction after UAE. Moreover, 
preinterventional MRI findings of
uterine leiomyomas give objective 
anatomical base for symptoms of 
leiomyomata patients.
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ABSTRACT
Uterine leiomyomas constitute a substantial health issue for women and represent the most common
single indication for hysterectomy. New treatment option, uterine artery embolisation (UAE) has
been developed to substitute for major surgery but not evaluated in Finland.
The aim of this study was to compare the efficacy and safety of UAE and hysterectomy for the
treatment of symptomatic leiomyomas in a prospective, randomised, controlled single-center trial
with a 2-year follow-up. Further, magnetic resonance imaging (MRI) measures were used to assess
the association of symptoms with MRI findings of leiomyomas, to evaluate the role of uterine
ischaemia for  the post-UAE pain,  and to  predict  leiomyoma and uterus size  reductions after  UAE.
Altogether 137 of 529 consecutive patients ready for hysterectomy were recruited to the study during
2002-2007 in Kuopio University Hospital in Finland. Twenty-seven patients were randomised to
UAE and 30 to hysterectomy.
Analysed according to  intention to  treat,  no major  complications were encountered after  UAE,
while 7% of patients encountered major complications after hysterectomy. The mean hospitalisation
and length of sick leave were shorter after UAE than after hysterectomy (1.3 vs 3.5 days, P=0.001; 11
vs 35 days, P=0.001; respectively). Menorrhagia  relieved  in  67%  of  UAE  patients.  Improvement  of
pressure symptoms was reported more frequently by UAE patients than by hysterectomy patients
(95% vs 69%, P=0.029). Overall relief of symptoms (82% UAE vs 93% hysterectomy) and satisfaction
of the treatments (89% UAE vs 97% hysterectomy) were good in both groups. Additional
interventions were  needed  in  19%  after  UAE  and  in  10%  after  hysterectomy. Of preinterventional
MRI characteristics, presence of a leiomyoma 50% protruding into uterine cavity, intense contrast
enhancement  of  leiomyomas  and  smaller  leiomyoma  size  were  associated  with  menorrhagia.  The
large uterine and leiomyoma size  were associated with increased urinary frequency,  while  urinary
stress incontinence, abdominal pain, and pressure to back were not associated with any MRI finding.
Myometrial ischaemia on 24-hour MRI and large volume of embolic material were associated with
post-UAE  pain  that  was  often  severe.  Leiomyoma  and  uterus  size  reductions  after  UAE  were
predicted by leiomyoma-to-skeletal muscle T2 SI-ratio and T1-time of the pre-UAE MRI.
In summary, UAE is a safe and effective treatment for leiomyomas being preferable for patients
with pressure symptoms. MRI findings of leiomyomata uteri give anatomical base for menorrhagia
and increased urinary frequency. Post-UAE pain is partly explained by myometrial ischaemia.
Uterus and leiomyoma size reduction after UAE can be predicted from pre-UAE MRI measures.
National Library of Medical Classification: QZ 340, WN 185, WP 468
Medical Subjects Headings: Hysterectomy; Leiomyoma; Magnetic resonance imaging; Microspheres;
Prospective Studies; Randomized Controlled Trial; Treatment Outcome; Uterine Artery Embolization
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TIIVISTELMÄ
Kohdun hyvänlaatuiset myoomat vaikuttavat potilaan elämänlaatuun aiheuttaessaan runsasta
vuotoa (menorrhagia) ja lantion paineoireita. Ne ovat yleisin yksittäinen kohdunpoiston syy.
Kirurgisen hoidon vaihtoehdoksi on kehitetty uusi hoito, kohtuvaltimoiden embolisaatio (UAE).
Tutkimuksen tarkoituksena oli selvittää UAE:n tehokkuutta ja turvallisuutta oireisten
myoomapotilaiden hoidossa vertaamalla sitä kohdunpoistoleikkaukseen satunnaistetussa kahden
vuoden seurantatutkimuksessa. Toisena tavoitteena oli arvioida magneettikuvauslöydösten (MRI) ja
potilaan oireiden yhteyttä, UAE:n jälkeisen kivun liittymistä MRI-kuvassa näkyvään kohtulihaksen
iskemiaan ja MRI-mittausten ennustavuutta kohdun ja myoomien koon pienenemiseen.
Tutkimukseen rekrytoitiin vuosina 2002-2007 Kuopion yliopistollisen sairaalan
naistentautipoliklinikalta peräkkäisiä naisia (137/529), joilla oli kohdunpoiston kriteerit täyttävä
myoomatauti. Heistä 27 satunnaistettiin embolisaatioon ja 30 kohdunpoistoon.
Tuloksista ilmeni intention-to-treat –menetelmällä, että vakavia komplikaatioita ei esiintynyt
emboloiduilla, mutta leikatuista niitä oli 7%:lla. Sairaalassaoloaika ja sairausloman pituus olivat
lyhyemmät UAE:n jälkeen (1.3 vs 3.5 vrk, P=0.001; 11 vs 35 vrk, P=0.001). Kahden vuoden seuranta-
aikana runsaat vuodot vähenivät 67%:lla emboloiduista. Paineoireet korjautuivat paremmin UAE:n
jälkeen (95% vs 69%, P=0.029). Kokonaisuudessaan myoomiin liittyvien oireiden vähentymisessä ja
tyytyväisyydessä hoitomuotoon ei ollut merkitsevää eroa (82% UAE vs 93% kohdunpoisto; 89% UAE
vs 97% kohdunpoisto). Emboloiduista 19% ja leikatuista 10% tarvitsivat lisähoitoja seuranta-aikana.
MRI-löydöksistä tilavuudestaan yli 50% kohtuonteloon työntyvä myooma, myoomien voimakas
tehostuminen ja pienempi koko liittyivät menorrhagiaan ja myoomien suuri koko tihentyneeseen
virtsaamistarpeeseen. Mikään MRI-löydöksistä ei liittynyt ponnistusinkontinenssiin,
alavatsakipuihin tai selkään suuntautuviin paineoireisiin. Kohtulihaksen iskemia 24 tunnin MRI:ssä
ja embolisaatiopartikkeleiden suuri määrä liittyivät kovaksi koettuun kipuun. Myoomien ja kohdun
koon pieneneminen olivat yhteydessä myooman ja lihaskudoksen T2-signaalien suhteeseen ja T1-
aikaan.
Tulokset  osoittavat,  että  UAE  on  turvallinen  hoitomuoto  ja  tehokas  varsinkin  paineoireista
kärsiville myoomapotilaille. MRI-löydökset liittyvät menorrhagiaan ja tihentyneeseen
virtsaamistarpeeseen. UAE:n jälkeinen kohtulihaksen iskemia selittää toimenpiteen jälkeistä kipua.
MRI-mittauksilla voidaan ennustaa UAE:n jälkeistä kohdun ja myooman koon pienenemistä.
Luokitus: QZ 340, WN 185, WP 468
Yleinen suomalainen asiasanasto: embolisaatio; kohdunpoisto; magneettitutkimus; myoomat –
hoitomenetelmät; seurantatutkimus
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1 Introduction
Uterine leiomyomas are the most common solid benign
pelvic tumors in women during reproductive life (Wallach et al.
2004). An estimated 20-50% of leiomyomas are to produce
symptoms (Buttram et al. 1981, Stovall 2001), such as prolonged
or heavy menstrual bleeding (menorrhagia) and different
pressure feelings in the pelvic area (Bukulmez et  al. 2006).
Menorrhagia may cause medical problems, but it also is a
powerful source of social embarrassment and lost productivity
for women at working life. Thus, leiomyomas have a major
impact on quality of life and health (Pron et al. 2003a, Williams
et al. 2006).
Surgical hysterectomy has been the standard treatment for
leiomyomas, and symptomatic leiomyoma has been the single
most common (in 2008, 39%) indication for hysterectomy in
Finland (National Institute for Health and Welfare 2009,
Brummer et al. 2009). As an alternative to surgery, uterine artery
embolisation (UAE), by occluding the vascular supply of
leiomyomas, has recently increasingly been applied worldwide
(Goodwin et  al. 2008, Tropeano et  al. 2008). However, UAE is a
rather novel treatment for leiomyoma patients and it  has  not
been evaluated in Finland. Thus, it is important to investigate
the effectiveness and safety of UAE, and patient satisfaction
with this less invasive treatment.
There are several aspects associated with UAE not fully
understood,  indicating  the  need  for  a  more  thorough  study.
UAE can result in significant postprocedural pain as a primary
adverse effect (Goodwin et  al. 1999, Lampmann et  al. 2007,
Worthington-Kirsch et al. 1998) possibly reducing the
satisfaction to the therapy. Furthermore, although the basic
clinical rationale is that only symptomatic patients will be
treated, it has not been scientifically evaluated which patients
get the best benefit from UAE. Therefore, it would be very
2useful if we could predict from preprocedural imaging findings
which  uterine  leiomyomas  will  respond  most  favourably  to
UAE.
Transvaginal ultrasound imaging is used as a first imaging
method to confirm the presence of leiomyomas. However,
magnetic resonance imaging (MRI) has been suggested to be a
highly accurate, noninvasive method for diagnosis of female
pelvis pathology (Kirby et al. 2010, Murase et al. 1999). Although
the typical MRI findings in patients with uterine leiomyomas
are well established, the precise relationships between the size
and location of uterine leiomyomas and their clinical
implications are still unclear and results about associations
between symptoms and leiomyoma MRI characteristics have
been controversial (Gupta et al. 2008, Parker 2007, Viswanathan
et al. 2007). Indeed, while various patient complaints are often
attributed to leiomyomas, it is probable that not all pressure and
pain symptoms are leiomyoma-related. Even the association
between menorrhagia and leiomyomas is ambiguous. Therefore,
establishment of the correct diagnosis is mandatory to avoid
unnecessary therapeutic interventions and to inform the patient
of likely treatment outcomes.
32 Review of the Literature
2.1 UTERINE LEIOMYOMAS
2.1.1 Etiology, Histopathology, and Epidemiology
Uterine leiomyomas are benign gynecological neoplasms of
the uterus (Wallach et al. 2004). These tumors typically develop
in women at fertile age, increase with age, and shrink after the
menopause (Viswanathan et al. 2007), but hormone replacement
therapy may even stimulate growth (Flake et  al. 2003). Despite
extensive research on the factors involved in the growth of
leiomyomas, the precise causes of these tumors still remain
unknown. Several predisposing factors have been identified,
including age (late reproductive years), nulliparity, obesity, and
African-American ethnicity (Flake et  al. 2003). The growth of
leiomyomas is ovarian hormones-dependent, i.e. estrogen and
progesterone dependent. Actually these tumors contain
estrogen and progesterone receptors (Zaloudek et  al. 2002).
Growth factors with mitogenic activity also are elevated in
leiomyomas (Flake et  al. 2003). Further, there is increasing
evidence of genetic basis; previously mapped gene predisposes
multiple leiomyomas and is related to familial leiomyomata
(Tomlinson et al. 2002).
Histologically, leiomyomas are mesenchymal tumors and
are easily identified as being of smooth muscle origin and
benign, and they seem to be proliferation of a single clone of
smooth muscle cell (Zaloudek et  al. 2002). Leiomyomas can be
located anywhere in the myometrium and are classified
according to their location in the uterus: submucosal (projecting
into the endometrial cavity and compressing the overlying
endometrium), intramural (within the myometrium), and
subserosal (beneath the serosa). Intramural location seems to be
the most common. Submucosal leiomyomas can be
pedunculated protruding to the uterine cavity, and subserosal
4leiomyomas as pedunculated can lose its connection with
uterus. Rarely, some become attached to another pelvic
structure. Leiomyomas may be single or, more frequently,
multiple. The size of uterine leiomyomas is variable, ranging
from microscopic to extremely large tumors (Murase et al. 1999).
Different degenerative changes are common in leiomyomas,
hemorrhage and necrosis can be observed in leiomyomas, and
some leiomyomas become extensively calcified (Zaloudek et  al.
2002). Sarcomatous change of a previously benign leiomyoma to
malign leiomyosarcoma is rare (Kitamura et  al. 2005, Rha et  al.
2003, Wallach et al. 2004).
Uterine leiomyomas are the most common pelvic
gynecological tumors (Flake et  al. 2003, Wallach et  al. 2004),
occurring with a remarkable frequency in more than 70% of
reproductive age women (Cramer et  al. 1990). Most uterine
leiomyomas cause no symptoms (Buttram et al. 1981), and these
tumors can be incidental (Zaloudek et  al. 2002). However,
leiomyomas have a major impact on the resources of health care,
as they can cause significant morbidity (Brummer et al. 2009).
Although the phrase “uterine fibroid” is commonly used, for
the purposes of clarify and scientific accuracy in this thesis, the
colloquial term “fibroid” will not be used according to the
standards of The Society of Interventional Radiology (SIR)
(Hovsepian et al. 2009, Stokes et al.2010).
2.1.2 Symptoms
Most of women with uterine leiomyomas are asymptomatic.
When symptomatic, leiomyomas may present with heavy
prolonged menstrual bleeding (i.e. menorrhagia) (Stewart 2001),
pain and a sensation of pressure or an uncomfortable feeling in
pelvic area, increased urinary frequency, bloating, constipation,
and rarely reproductive dysfunction (Buttram et  al. 1981,
Wallach et  al. 2004). Menorrhagia may result in iron-defiency
anaemia.
Although leiomyomas are common, the relationship
between symptoms and leiomyomas is not clear. Results of
previous studies are contradictory in assessing the association
5between symptoms and MRI derived leiomyoma characteristics.
Indeed, the factors that determine who get symptoms are
unknown (Viswanathan et  al. 2007). Studies imply that
symptoms  may  depend  on  the  location,  size,  and  number  of
leiomyomas (Buttram et al. 1981). Submucosal leiomyomas may
be more likely to cause menorrhagia (Stewart 2001), although
large intramural leiomyomas that distort the endometrial cavity
may also result in heavy bleeding (Clevenger-Hoeft et al. 1999).
On the other hand, the cause of heavy bleeding in leiomyomata
uterus without submucosal component is unresolved.
Large intramural and subserosal leiomyomas or large uteri
with numerous leiomyomas may produce a pressure feeling to
the adjacent organs, typically as located in the anterior part of
uterus to the urinary bladder leading to increased urinary
frequency and occasionally as located in the posterior part of the
uterus to the bowel leading to constipation (Stewart 2001). An
estimated 30% of women with uterine leiomyomas experience
abdominal pain (Hutchins 1995), but the results about the
association of  the lower abdominal pain with leiomyomas have
been controversial. Particularly hemorrhagic degeneration may
be related with pain symptoms (Kawakami et al. 1994, Murase et
al. 1999). In addition, acute pain can be caused by torsion of the
pedicle of a pedunculated leiomyoma, or cervical dilatation by a
submucosal leiomyoma protruding through the lower uterine
segment (Wallach et al. 2004).
2.1.3 Clinical Evaluation
Leiomyomas are usually found incidentally in the
gynecologic examination due to enlarged and deformed uterus.
Bimanual palpation and estimation of the size of the uterus
forms an important part of the examination. Transvaginal
ultrasound performed by a gynecologist is the most readily
available imaging technique and typically used to confirm the
diagnosis and to exclude the possibility of other pelvic
pathology. Transvaginal ultrasound should be used initially in
clinical practice because it is the least invasive and most cost-
effective tool (Evans et al. 2007). However, it may be inadequate
6for determining the precise number and location of leiomyomas,
particularly in the presence of large uteri. Three-dimensional or
saline-infusion transvaginal ultrasound or hysteroscopy can be
performed for confirming in case of uncertainty of sumucosal
location.
Because the symptoms associated with leiomyomas can also
be of other etiologies, it is mandatory that patients undergo
adequate preprocedural evaluation. A Papanicolau test, and in
the presence of significant bleeding symptoms, an endometrial
biopsy should be performed and a recent blood count should be
available.
2.1.4 Diagnostic Imaging
Although transvaginal ultrasound should be used initially in
clinical practice because it is the least invasive and most cost-
effective tool (Evans et  al. 2007), MRI is an ideal tool for
evaluating the characteristics of large uterine leiomyomas and
especially leiomyoma location (Dueholm et  al. 2002, Spielmann
et al. 2006). Computed tomography is used sometimes due to
poor availability of MRI. However, the high patient radiation
dose decreases its usability in imaging leiomyomas. Further,
advantages of MRI include increased spatial resolution and
improved anatomic detail (Kirby et al. 2010).
2.2 MAGNETIC RESONANCE IMAGING OF LEIOMYOMAS
MRI, as a non-invasive tool, provides the most accurate
assessment and excellent visualization of leiomyomas, as well as
their size, location, and impact on adjacent structures (Dueholm
et al. 2002, Dueholm et  al. 2001, Hricak et  al. 1986, Murase et  al.
1999, Spielmann et  al. 2006). Further, contrast-enhanced MRI
before treatment can be used to determine the viability of
leiomyomas and to detect other findings that would influence
choosing the treatment (Nikolaidis et  al. 2005). MRI can also be
used to evaluate technical success of UAE and to image possible
complications after UAE (Kirby et al. 2010).
7Appearance of Leiomyomas
MRI of leiomyomas relies on T2-weighted fast spin echo
sequences (Kirby et  al. 2010). Nondegenerated uterine
leiomyomas have a typical appearance on MRI: well-
distinguishable and well-circumscribed tumors of
homogenously decreased signal intensity (SI) compared with
that of the myometrium in T2-weighted images (Hamlin et  al.
1985, Hricak et al. 1986, Jha et al. 2000, Kido et al. 2003, Murase et
al. 1999, Riccio et  al. 1990) and considerable homogenous
(cellular leiomyoma) enhancement equally to the myometrium
on gadolinium enhanced sequences (Yamashita et al. 1993). On
T1-weihted sequences, most leiomyomas are isointense to
surrounding myometrium.
Gadolinium-enhanced MRI can distinguish nondegenerated
leiomyomas from non-enhanced degenerated ones (Okizuka et
al. 1993). Degenerated leiomyomas may show minimal and
irregular enhancement and have variable appearances in T2-
weighted images: higher SI and heterogeneous architecture
(Yamashita et  al. 1993). Further, leiomyomas with necrosis or
with hyaline or calcific degeneration have low SI in T2-weighted
images, while cystic degeneration shows high SI in T2-weighted
images (Murase et  al. 1999). Myxoid degeneration show very
high SI in T2-weighted images and a minimal enhancement
(Murase et  al. 1999). Red degeneration (hemorrhagic infarction)
may present with a variable signal pattern: periferal or diffuse
high SI in T1-images and variable SI with a possible low-signal-
intensity rim in T2-images (Kawakami et  al. 1994). The signal
characteristics of the rim can be explained as an effect of
methemoglobin (Kawakami et al. 1994).
Differential Diagnosis
The differential diagnosis of leiomyomas on MRI includes
adenomyosis, solid adnexal tumors, focal myometrial
contraction, and uterine leiomyosarcoma (Murase et al. 1999).
Adenomyosis, as the diffuse form, appears as a thickening of
the junctional zone (inner myometrium), whereas focal
adenomyosis appears as a ill-defined low-signal-intensity mass
8poorly marginated from the adjacent myometrium in T2-
weighted images (Kido et al. 2003, Mark et al. 1987). In addition,
bright spots are identified in T1- or T2-weighted images in
adenomyosis (Kido et al. 2003).
Uterine myometrial contractions may simulate leiomyomas
manifesting as a myometrial mass of low SI in T2-weighted
images (Murase et al. 1999).
MRI findings that allow distinction between benign
leiomyoma and malignant leiomyosarcoma are not fully
established. Nevertheless, the infiltrative margins, rapid growth
(Kido et  al. 2003), or high SI within a uterine mass on T1-
weighted and on T2-weighted images (Tanaka et al. 2004), or the
invasion or metastatic spread may be indications of malignancy
(Weinreb et  al. 1990). Recently, the diffusion-weighted imaging
has been evaluated in differentiating benign leiomyomas from
sarcomas (Namimoto et  al. 2009, Takeuchi et  al. 2009). These
results show that a combination of T2-weighted sequence and
diffusion-weighted imaging improves sensitivity and specificity
(Namimoto et al. 2009).
Further, MRI allows differentiation between pedunculated
leiomyomas and adnexal masses due to the ability to
demonstrate normal ovaries and the continuity or discontinuity
of an adnexal mass with myometrium (Weinreb et al. 1990,
Zawin et al. 1990).
2.3 TREATMENT OF LEIOMYOMAS
The aims of leiomyoma treatments are to reduce the
symptoms considered to be related to leiomyomas; to reduce
menstrual bleeding and pressure symptoms and pelvic pain, to
correct the iron deficiency anaemia, and in selected cases, to
improve fertility.
2.3.1 Hysterectomy and Myomectomy
Hysterectomy is the most common surgical treatment for
leiomyomas for the women who have completed childbearing
9(ACOG 2008). The main indication for hysterectomy in Finland
is leiomyomas being 33-39% of all hysterectomies (2009,
Brummer et  al. 2009). The total number of hysterectomies on
benign indications has decreased in Finland during years 2000-
2008 from 10 000 to 7 000 (National Institute for Health and
Welfare 2009, Brummer et al. 2009, Brummer et al. 2008) since a
variety of new treatment approaches have become available
(Tropeano et al. 2008). Indeed, as high as 50% of all
hysterectomies was performed for leiomyomas two decades ago
(Luoto et  al. 1994a, Luoto et  al. 1994b). Further, the Ministry of
Social Affairs and Health in Finland has published the uniform
criteria for non-emergency surgical hysterectomy for
leiomyomas in 2005 (updated in 2010) (The Ministry of Social
Affairs and Health 2010). According to these recommendations
the hysterectomy is indicated if the score of 50 is gained: 50
points for leiomyoma over 10 cm in diameter or the greatest
diameter of uterus over 20 cm; 30 points for submucosal
leiomyoma, menorrhagia, a pressure feeling in pelvis, or
urinary, defecation, or pain symptoms; and 20 points for the
ineffective conservative treatments.
Laparoscopic and vaginal hysterectomies have become more
common for benign indications comparing to abdominal route
in Finland during recent years (Brummer et al. 2008) shortening
the operation time, hospital stay, and sick leave (Brummer et al.
2009). Nevertheless, the hysterectomy is an invasive procedure
with a risk of major complications (about 1% during years 2000-
2005), such as urinary tract injury (ureteral or bladder injury),
bowel injury, and hemorrhage (Brummer et  al. 2008). Blood
transfusions were given to 5 % of patients in the prospective
nationwide FINHYST study (Brummer et al. 2009).
Myomectomy with various techniques is considered a
treatment option for women who wish to preserve the
possibility of pregnancy (Lumsden 2002). Abdominal
myomectomy has been traditionally used. Laparoscopic
myomectomy would be a treatment option for patients with
subserosal or intramural leiomyomas, whereas submucosal
leiomyomas can be removed by hysteroscopic myomectomy
10
(Lefebvre et al. 2003, Rovio et al. 2009). Vaginal myomectomy is
achieved via colpotomy (Rovio et  al. 2006). The proportion  of
myomectomies of leiomyoma treatments has been about 14% in
Finland (National Institute for Health and Welfare 2009).
2.3.2 Uterine Artery Embolisation
UAE has been available from late  1970s, initially as a
technique for postpartum and pelvic hemorrhage (Brown et  al.
1979, Heaston et  al. 1979, Pelage et  al. 1998, Pelage et  al. 1999a,
Walker 1996, Walker et  al. 1980). More recently, in 1995, it was
reported for the treatment of symptomatic uterine leiomyomas
(Ravina et al. 1995). The technique was used pre-surgery for
limiting blood loss, but due to cessation of symptoms the
surgery was cancelled. Since then, UAE has been under interest
and research by interventional radiologists and gynecologists
around the world. The greatest amount of data from the new
technologies of the minimally invasive treatments for
leiomyomas is of UAE (Sharp 2006). It has become increasingly
available in treating leiomyomas, and currently approximately
25000 UAE procedures are now performed worldwide annually
(Goodwin et al. 2008). However, in a recent study by Voogt et al.
the authors found the marked variation in current practise of
UAE in European countries (Voogt et al. 2010).
2.3.2.1 Indications
SIR recommends that UAE be offered to only patients with
uterine leiomyomas that are causing significant symptoms
(heavy menstrual bleeding, pain, and bulk-related symptoms)
(Andrews et  al. 2009, Stokes et  al. 2010). UAE represents a
reasonable option especially for those who are at risk increased
risk in the setting of surgery, or desire uterine preservation
(Stokes et al. 2010).
2.3.2.2 Contraindications
From the start, a viable pregnancy, active untreated
gynecological infection, and gynecological malignancy have
been considered absolute contraindications to UAE (Andrews et
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al. 2009). Since then, SIR and Cardiovascular and Interventional
Radiological  Society  of  Europe  (CIRSE)  have  aimed  to  unify
these recommendations (Hovsepian et  al. 2009, Stokes et  al.
2010). Relative contraindications may be any conditions that
may interfere with the normal healing response and place the
patients at a higher risk of complications; immunocompromise,
previous pelvic irradiation or surgery, chronic endometritis,
coagulopathy, severe contrast material allergy, and renal
impairment.
There are some leiomyoma locations or morphologic
features that may make leiomyomas less ideal for embolisation,
including narrow-based pedunculated or broad-ligament
leiomyomas, and intracavitary leiomyomas (Kirby et al. 2010).
For  patients  with  a  history  suggesting  an  underlying
bleeding disorder that may be contributing to menstrual
bleeding or may complicate percutaneus therapy, activated
thromboplastin time and prothrombin time are recommened to
be measured before UAE (Andrews et al. 2009).
At the time being, UAE is not recommended as a primary
therapy for patients who desire to maintain fertility and
childbearing potential; myomectomy seem to be an advisable
treatment option for them (Goldberg et  al. 2006, Usadi et  al.
2007). Uncertainty about fertility after UAE has led to recent SIR
guidelines that suggested that UAE is a relative contraindication
for patients who wish to retain their fertility but may also
represent the preferred alternative for patients who are not able
to undergo a myomectomy (Hovsepian et  al. 2009). The recent
systematic literature review and meta-analysis of published
studies identified altogether 227 completed pregnancies after
UAE and the authors concluded that the risk of miscarriage
seems to be increased after UAE (Homer et al. 2010). In contrast,
one retrospective study found that UAE patients had better
success rate than myomectomy recipients (Narayan et al. 2010).
Uncomplicated pregnancies and normal deliveries after UAE
have also been reported in other studies (Carpenter et  al. 2005,
Dutton et al. 2007, Goldberg et al. 2004, Holub et al. 2008, Kim et
al. 2005, Mara et al. 2008, Pron et al. 2005, Walker et al. 2006a).
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2.3.2.3 Technique
The goal of UAE is to deliver particulate emboli into both
uterine arteries for the purpose of occluding or markedly
reducing uterine flow at the arteriolar level, producing an
irreversible ischaemic injury to the leiomyomas while avoiding
permanent damage to the uterus (Marshburn et  al. 2006, Stokes
et al., Tropeano et al. 2008).
Technique
The procedure is performed under fluoroscopic guidance
under local anestesia and sometimes, if the patient demands,
under conscious sedation. Percutaneus access is achieved
through one or both femoral arteries; usually the unilateral
approach is used via a right femoral artery. Some authors
recommend routine aortography before embolisation with
attention given to the presence of anomalious uterine arterial
anatomy, especially possible supply from ovarian artery.
However, a common practise is to perform aortography only in
case that uterine artery anatomy is unusual (e.g. hypoplastic).
Direct selective catheterization of both uterine arteries is
performed  with  a  4  -  or  5-French  Cobra  or  Simmons  shape
catheter. In case of arterial spasm or difficult access selective
catheterisation may require the use of micro-catheters and
vasodilator agents to reduce the likelihood of technical failure.
The catheter is placed approximately halfway along the uterine
artery distally to the cervicovaginal branches, if possible. An
arteriogram is obtained to visualize the anatomy of the arterial
plexus supplying the leiomyoma. Then mixture of embolisation
particles and contrast agent is slowly injected into the uterine
artery during fluoroscopic monitoring carefully avoiding
embolisation of ovaries through uterine-ovarian artery
anastamoses and inadvertent reflux into other arterial branches.
After the procedure, hemostasis at the puncture site is achieved
by bimanual compression or by means of a vascular closure
device.
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Medication
Prophylactic antibiotics are routinely administered before
and after embolisation to reduce the risk of infections (Goodwin
et al. 2009). Administration of intravenous narcotics for often
severe postprocedural pain and the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) are standard. Many analgesia
protocols  have  been  described  for  UAE,  varying  from NSAIDs
and paracetamol to patient-controlled analgesia and to standard
epidural anesthesia in some centers (Hehenkamp et  al. 2006,
Lampmann et  al. 2007). An adequate and extensive pain
management protocol for UAE is extremely important for the
periprocedural and especially for the postprocedural period
(Lampmann et  al. 2007). UAE usually requires an overnight
hospital stay for observation and intravenous pain medication.
Angiographic Endpoint
A number of angiographic endpoints have been used.
Originally the technique of total occlusion, where embolisation
particles are injected until flow in the uterine artery stops, was
used. Recently, the limited embolisation, defined as a complete
occlusion  of  branches  to  the  peritumoral  plexus  and  sluggish
flow in the ascending segment of the uterine artery, leaving the
main uterine artery, normal myometrial branches,
cervicovaginal branches, and utero-ovarian anastomoses patent
has become more popular (Joffre et  al. 2004, Lohle et al. 2008,
Pelage et  al. 2003). This less aggressive embolisation of the
uterine arteries may lead to the same clinical success rate, and
reduced postprocedural pain and complications compared with
complete embolisation (Pelage et al. 2003, Spies et al. 2001a).
The best method of achieving effective embolisation is still
not evidence based. Even then, the technical success has been
88-99% in published studies (Joffre et  al. 2004, Lohle et  al. 2008,
Pinto et al. 2003, Prollius et al. 2004, Pron et al. 2003b, Scheurig et
al. 2006, Worthington-Kirsch et  al. 2005). Variant anatomy of
vessels seems to be the most common reason for failure to
embolise bilaterally (Pron et al. 2003b, Volkers et al. 2006).
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Embolic Agents
Several embolic agents have been available. UAE with
calibrated tris-acryl gelatine microspheres (TAGM) (Laurent et
al. 1996), polyvinyl alcohol (PVA) particles, gelatin sponge
pledgets, and platinum coils have been reported (Joffre et  al.
2004, Lohle et al. 2008, Scheurig-Muenkler et al. 2010, Spies et al.
2004a, Spies et al. 2007, Walker et al. 2002, Worthington-Kirsch et
al. 2005).
One randomised study comparing PVA particles and
TAGMs showed no differences in pain severity, in the frequency
of incompletely infarcted leiomyomas, in the degree of
improvement in symptoms score, or in patient satisfaction
(Spies et  al. 2004a). On the other hand, in other prospective
randomised studies a significantly greater degree of leiomyoma
infarction was obtained in patients embolised with microsphere
particles than in those embolised with PVA particles (Siskin et
al. 2008, Spies et  al. 2005a). Actually, large (700-900μm)
microsphere particles appear to penetrate significantly deeper
into the leiomyoma compared with PVA particles (Chua et  al.
2005). Further, spherical microsphere particles do not clump or
aggregate leading to more controlled arterial occlusion and a
precisely targeted tumor devascularization possibly with less
extensive occlusion (Pelage et al. 2002).
Acrylamido PVA microspheres have also been shown to be
an effective and safe embolic agent for UAE (Kroencke et  al.
2008). This agent is in many ways similar to TAGMs
(Worthington-Kirsch et  al. 2010). One randomised study used
acrylamido PVA microspheres instead of PVA particles to
compare with TAGMs; no differences were found in perfusion
scores of leiomyomas evaluated by 6-month MRI and in disease-
specific symptom and health-related quality of life scores
(Worthington-Kirsch et al. 2010).
Concerning the particle size, a prospective randomised
study with 160 patients concluded that the use of PVA particles
sizes 350-500μm was associated with higher pain scores
compared to the use of particles sizes 500-700μm, but there was
no differences in the decrease in size of leiomyoma, in the
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leiomyoma ischaemia, or in the clinical outcome (Bilhim et  al.
2011).
Radiation Dose
The uterus, ovaries, and urinary bladder are in the direct
radiation beam and cannot be shielded in UAE. Further, the
gonads are among the most radiation-sensitive organs in any
individuals.  Thus,  to  measure  and  document  the  fluoroscopy
time, the number of images and the dose-area-product (DAP)
for each individual UAE patient should be a standard practise in
the interventional radiology.
Previous studies have reported mean fluoroscopic times
between 14 and 36 minutes (Andrews et  al. 2000, Glomset et  al.
2006, Miller et al. 2003, Sapoval et al. 2010, Vetter et al. 2004). The
mean DAP values has varied between 30 and 411 Gycm2
depending on different techniques and equipments (Andrews et
al. 2000, Glomset et al. 2006, Miller et al. 2003, Sapoval et al. 2010,
Vetter et al. 2004).
Many factors may influence on the variation of patient
doses, for example the difference of embolisation techniques,
experience of the interventional radiologist, and the difference
in patients’ anatomy. It has been shown that the fluoroscopic
time seems to correlate with the experience of the interventionist
(Andrews et al. 2000, Pron et al. 2003c, Walker et al. 2002). Bratby
et al. showed shorter fluoroscopic time when simultaneous
embolisation of both uterine arteries was used with bilateral
puncture of the groin (Bratby et  al. 2007). Further, the use of
pulsed fluoroscopy reduced ovarian dose significantly in two
studies (Glomset et al. 2006, Nikolic et al. 2001). In addition, the
use of low-dose and low-frame fluoroscopy and angiography
(Sapoval et  al. 2010) and the greater filtration (Glomset et  al.
2006) allow a significant decrease in the patient dose. Thus, UAE
requires the use of the highest-quality fluoroscopic equipment,
and adequate training is essential for the performing physician
(Spies et al. 2009a).
In one prospective study, where the procedures were
performed by an experienced interventional radiologist in UAE,
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the main component (about 50%) of the total DAP was the
embolisation itself (White et  al. 2007a). The same authors also
showed that 20% of the total dose was related to the abdominal
aortography. Aortography is usually performed to find the
residual ovarian artery supply to the uterus after the completion
of embolisation (Pelage et  al. 2005). However, the utility of
aortography in routine UAE is not clear, because of the small
number of patients with substantial ovarian artery collateral
supply and of the low sensitivity of aortography in the
identification of this supply (White et  al. 2007b).
Preinterventional magnetic resonance angiography can help to
predict ovarian artery supply of uterine leiomyomas while
minimizing radiation exposure of conventional angiography
during UAE (Kroencke et al. 2006).
2.3.2.4 Treatment Outcome
The initial clinical studies of UAE for leiomyomas were
promising in short- and mid-term follow-up (Pelage et  al. 2000,
Ravina et  al. 1995, Spies et  al. 1999). In recent years many
multicenter follow-up trials have been carried out (Goodwin et
al. 2008, Myers et  al. 2005, Pron et  al. 2003a, Pron et  al. 2003b,
Pron et  al. 2003c, Pron et  al. 2005, Pron et  al. 2003d, Pron et  al.
2003e, Spies et  al. 2007, Spies et  al. 2005b, Walker et  al. 2006b,
Walker et  al. 2002, Watson et  al. 2002, Worthington-Kirsch et  al.
2005).
The treatment seems to be well tolerated. Studies have
suggested that recovery is rapid, a short hospital stay (1-3 days)
(Bruno et  al. 2004) and sick leave (1-2 weeks) are required in
most cases (Pron et al. 2003d, Siskin et al. 2000, Walker et al. 2002,
Worthington-Kirsch et  al. 2005). Reports indicate that UAE
appears to be effective in controlling the leiomyoma-related
symptoms. The improvement of bleeding symptoms has been
shown in 60-90% of patients and the relief of pressure and pain
symptoms in 70-90% of women (Hirst et  al. 2008, Joffre et  al.
2004, Prollius et  al. 2004, Pron et  al. 2003c, Spies et  al. 2005c).
Patients’ satisfaction with treatment seems to be high varying
between 82-97% (Goodwin et al. 2008, Lohle et al. 2008, Prollius
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et al. 2004, Spies et  al. 2005b, Walker et  al. 2002), and UAE
appears to result in a durable improvement of quality of life
(Goodwin et al. 2008, Spies et al. 2005c). On the other hand, quite
large proportion of patients has been lost to follow-up.
The response of the leiomyomas in terms of decrease in size
has been variable. However, remarkable reduction in the uterine
and largest leiomyoma volumes have been demonstrated in
follow-up ultrasound and MR imaging (Hirst et al. 2008, Joffre et
al. 2004, Pinto et  al. 2003, Prollius et  al. 2004, Pron et  al. 2003c,
Scheurig et al. 2006, Spies et al. 2001b, Walker et al. 2002, Volkers
et al. 2007). MRI seems to be useful follow-up technique after
UAE to visualise outcome of treatment (Banovac et  al. 2002,
Burn et  al. 2000, deSouza et  al. 2002, Jha et al. 2000, Pelage et  al.
2004). In particular, gadolinium enhanced MRI provides unique
information for assessing the degree of infarction in the
embolised leiomyomas after UAE (Katsumori et  al. 2007,
Katsumori et al. 2001).
Recent studies have shown that clinical failure may be
associated with incomplete infarction of leiomyomas (Banovac
et al. 2002, Pelage et  al. 2004) as well as newly developed
leiomyomas (Kim et  al. 2010). Besides technical causes,
additional ovarian artery supply of leiomyomas has been
suggested as a cause of noninfarcted leiomyomas (Matson et al.
2000, Nikolic et  al. 1999). Even with complete infarction of all
leiomyomas, a viable uterus may give a rise to new leiomyomas.
New leiomyomas growth was found in 20% of patients on MRI
at 3-years follow-up (Pelage et al. 2004) and in 30% of patients at
the mean follow-up of 5.8 years (Kim et  al. 2010). Thus,
evaluation with contrast-enhanced MRI is emerging as an
essential part to assessing outcome of UAE (Spies 2009b). The
need of additional intervention (hysterectomy, myomectomy, or
repeat UAE) among patients in published studies has varied 8-
28% in the long-term follow-up usually due to uncontrolled
bleeding symptoms (Goodwin et  al. 2008, Hirst et  al. 2008,
Narayan et al. 2010, Spies et  al. 2005c, Spies et  al. 2007, van der
Kooij et al 2010.).
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2.3.2.5 Complications
SIR and CIRSE have defined the complications on the basis
of outcome (Stokes et  al. 2010). Major complications result in
admission to hospital for therapy, an unplanned increase in the
level of care, prolonged hospitalisation, permanent adverse
sequelae or death; minor complications result in no additional
interventions and required no therapy or at most nominal
therapy or overnight hospital stay for observation only.
The rate of complications has varied in individual studies
perhaps due to different definitions of complications. The rate of
minor complications has generally been around 5-20% and the
rate of major complications at most a few percentages (Hirst et
al. 2008, Spies et al. 2004b, Spies et al. 2002a, Worthington-Kirsch
et al. 2005).
Complications of catheterization procedure itself include
haematoma at the arterial puncture site, or vessel or femoral
nerve injury (Hovsepian et  al. 2009, Spies et al. 2002a); the
procedural complication rate was 5% in Ontario trial (Pron et al.
2003b).
Expected general side effects of UAE have been estimated to
appear in about 30% of UAEs (Hirst et al. 2008). Rather common
primary adverse effect of UAE is significant postprocedural pain
(Goodwin et al. 1999, Spies et al. 2002a, Worthington-Kirsch et al.
2005, Worthington-Kirsch et  al. 1998) that may lead to longer
hospital stay and hospital readmissions (Pron et  al. 2003d).
Treating this pain is essential but challenging (Lampmann et al.
2007). A few studies have evaluated postprocedural pain and
pain management (Hehenkamp et  al. 2006, Pron et  al. 2003d,
Siskin et al. 2002, Worthington-Kirsch et al. 1998), but the specific
cause of the pain is not fully understood. However, the data
imply that leiomyoma ischaemia and transient uterine
ischaemia, in particular, could be responsible for the immediate
postprocedural pain (Banovac et  al. 2002, Burbank 2004,
Burbank et al. 2000, Pelage et al. 2000, Ryu et al. 2003, Siddiqi et
al. 2006). This pain is expected for several hours after
embolisation and is not considered a complication unless
unplanned medical therapy, prolonged hospitalisation, or
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unexpected admission to the hospital is needed (Hovsepian et al.
2009, Stokes et al. 2010).
Postembolisation syndrome also is an expected aspect of
recovery and should not be considered a complication by the
same token (Hovsepian et  al. 2009, Stokes et al 2010.). It is
composed of pelvic pain, low-grade fever, nausea, vomiting,
loss of appetite, and malaise in the first few days after
undergoing UAE.
Natural expulsion of the whole or parts of the infarcted
leiomyomas has not been classified as complication (Burbank
2008). Further, vaginal discharge after UAE may occure. But
then, if infarcted and necrotic leiomyoma tissue is exposed to
the uterine cavity, there is risk of infectious complications
(Burbank 2008, Verma et al. 2008). There are infrequent reports
as individual cases of uterine infection, pyomyoma,
endometritis, and uterine necrosis (Spies et al. 2002a) possibly
leading to an emergent hysterectomy. The routine use of
antibiotics varies in clinics (Marshburn et al. 2006). According to
the HOPEFUL study prophylactic antibiotics seems to protect
against complications and side effects (Hirst et al. 2008).
Irregular menses, transient or permanent amenorrhea due to
ovarian failure have been reported after UAE (Spies et al. 2005b,
Walker et  al. 2002). It is possible for embolic agents to enter in
the ovarian vessels through collateral circulation with a decrease
in ovarians blood supply (Pelage et  al. 1999b, Ryu et  al. 2001)
leading to transient amenorrhea (12-28%) (Goodwin et  al. 2008,
Lohle et al. 2008, Spies et al. 2005c, Spies et al. 2004b, Spies et al.
2007). In a study by Chrisman et al. 15% of patients encountered
secondary amenorrhea, however, the premature ovarian failure
is rare among patients younger than 45 years (Chrisman et  al.
2000, Lohle et al. 2008, van der Kooij et al. 2010).
Major or potentially fatal complications occur very
infrequently; deep vein thrombosis, pulmonary embolus,
arterial thrombosis, nontargeted embolisation, urinary tract
infection, urinary retention, septicaemia, death, tubo-ovarian
abscess, or inadvertent embolisation of leiomyosarcoma being
reported (Hovsepian et al. 2009, Spies et al. 2002a).
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2.3.3 Other Uterus Sparing Treatments
There are a number of other new mini-invasive options for
the treatment of uterine leiomyomas. The magnetic resonance-
guided high intensity focused ultrasound (HIFU) ablation is a
hybrid technique using the heat-generating ability of ultrasound
combined with MRI, which provides anatomical guidance, the
real-time thermal monitoring, and postprocedural assessment of
the treatment extent (Al Hilli et  al. 2010, Cowan et  al. 2002,
Hesley et al. 2008).
Different techniques of myolysis via the laparoscopic or
hysteroscopic route have been demonstrated. Under ultrasound
monitoring, the fibers connected with laser energy are inserted
into the leiomyoma by laparoscopy in interstitial coagulation
(Visvanathan et  al. 2002), while cryomyolysis is performed by
destroying leiomyoma tissue with cryoprobe (Zupi et al. 2004).
The percutaneus approach is used in MRI guided thermo-
ablation with laser fibers (Law et  al. 2000) or in MRI guided
cryotherapy (Cowan et al. 2002).
Rather than embolising uterine arteries Hald et al.
demonstrated laparoscopic uterine artery occlusion where
uterine arteries are closed with the endoclips (Hald et  al. 2007,
Hald et al. 2004, Hald et al. 2009). Transvaginal Doppler-guided
uterine artery occlusion with a device containing a vascular
clamp has also been developed (Brill 2009).
Hormonal therapy is used to relieve symptoms associated
with uterine leiomyomas. Gonadotropin-releasing hormone
analogues/agonists (GnRHa) were thought to produce a
hypoestrogenic effect in various estrogen-dependent conditions,
e.g. uterine leiomyomas, by inhibiting gonadotropin secretion
and suppressing ovarian function (Wallach et  al. 2004). These
compounds have been reported to have an influence on
leiomyoma growth; the shrinkage of leiomyomas, decreasing
the uterine volume, and diminishing patient symptoms (Fiscella
et al. 2006, Wallach et  al. 2004). However, the effect of GnRHa
treatment is transient, and after discontinuing administration,
leiomyomas tend to return to their pretherapeutic size, and
symptoms commonly return (Wallach et  al. 2004). Some
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important side effects of hormonal therapy have been reported;
menopause, postmenopausal symptoms and osteoporosis.
2.3.4 Comparison of UAE with Other Treatments
Outcomes of comparative randomised trials of UAE and
hysterectomy and of comparative non-randomised multicenter
studies are summarized in Table 1.
Thus far, three randomised trials comparing UAE and
hysterectomy have been carried out: a Spanish singlecenter trial
by Pinto et al. (Pinto et al. 2003) with 60 randomised patients and
a 6-month follow-up, a multicenter REST trial in the UK with
157 randomised patients and a 12-month follow-up (Edwards et
al. 2007), and a multicenter EMMY trial in the Netherlands with
177 randomised patients and a 5-year follow-up (Hehenkamp et
al. 2006, Hehenkamp et al. 2008, Hehenkamp et al. 2005, van der
Kooij et al. 2010, Volkers et al. 2007, Volkers et al. 2006, Volkers et
al. 2008a).
The primary outcomes in the randomised trials have been as
follows: REST trial, quality of life (Edwards et al. 2007); Pinto et
al., the length of hospital stay (Pinto et  al. 2003);  and  EMMY
trial, clinical success with regard to if UAE could avoid a
hysterectomy in at least 75% of cases (Volkers et al. 2007). In
addition, a retrospective multicenter cohort study (HOPEFUL)
compared the safety and efficacy of UAE and hysterectomy
(Dutton et  al. 2007, Hirst et  al. 2008). One prospective
observational multicenter study compared the clinical outcome
of UAE and hysterectomy (Spies et al. 2004b).
In published studies patients in the UAE group seemed to
recover faster than patients in the hysterectomy group (Edwards
et al. 2007, Hehenkamp et al. 2006, Pinto et  al. 2003, Spies et  al.
2004b). The major complication rate has been significantly
higher after hysterectomy than after UAE in two studies (Dutton
et al. 2007, Pinto et  al. 2003), whereas REST and EMMY trials
reported no differences in major complication rate, but more
minor complications after UAE (Edwards et  al. 2007,
Hehenkamp et al. 2005). On the other hand, a definition of minor
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complication has varied in different studies making the
comparison of results difficult.
Results of improvement of pressure and pain symptoms
have been controversial (Spies et al. 2004, Volkers et al. 2007). In
two studies the improvement of symptom scores (Edwards et al.
2007) and of general health (Hirst et al. 2008) were significantly
better after hysterectomy than after UAE. On the other hand,
EMMY trial showed no difference in increase in quality of life
after the treatments (van der Kooij et  al. 2010). However, to
compare the results of general health and quality of life is
difficult due to different ways to perform the measurements in
the studies.
Total costs were significantly lower for UAE than for
hysterectomy in two randomised trials (Edwards et  al. 2007,
Volkers et al. 2008a). HOPEFUL study also indicated that UAE is
less expensive than hysterectomy even after further treatments
for unresolved or recurrent symptoms are taken into account
(Wu et al. 2007).
Similarly to UAE, myomectomy is not a definitive treatment
either. Mara et al. compared UAE and myomectomy in a
randomised controlled trial and found that there were no
differences in the technical or clinical success, or in the
complication rate, or in the number of reinterventions, but the
embolised patients underwent a shorter hospital stay and
recovery period (Mara et al. 2008).
Laparoscopic occlusion of uterine arteries also has been
compared to UAE in a randomised study that demonstrated
better improvement in bleeding symptoms after UAE than after
laparoscopic occlusion (Hald et al. 2007, Hald et al. 2009). On the
other hand, in another randomised trial UAE and laparoscopic
occlusion were comparable with regard to symptom relief
(Ambat et al. 2009).
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3 Aims of the Study
The general aim of the study was to compare UAE in
treating symptomatic leiomyoma patients with hysterectomy
and to evaluate pre- and post-UAE MRI findings of leiomyomas.
The more specific aims were:
I: To investigate the association between MRI derived
characteristics of uterine leiomyomas and treatment-worthy
symptoms; menorrhagia, and pressure and pain symptoms.
II: To prospectively compare UAE and hysterectomy for the
treatment of symptomatic leiomyomas, particularly the clinical
success at 2-year follow-up, in a randomised controlled trial.
III: To evaluate the frequency and extent of uterine ischaemia
after  UAE using  MRI  and to  study the  role  of  myometrial  and
leiomyoma ischaemia in the pathogenesis of postprocedural
pain.
IV: To investigate the relationship between pre-UAE MRI
measures and uterus and leiomyoma size reductions after UAE.
26
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4 Patients and Methods
4.1 STUDY DESIGN AND PATIENTS
The study protocol was approved by the Ethics Committee
of Kuopio University Hospital and written informed consent
was obtained from participating patients.
Figure  1 illustrates patient flow in the recruitment and
during the randomised study. During the recruitment period
(between 2002 and 2007) altogether 529 women were referred to
the gynecology outpatient clinic of Kuopio University Hospital
due to symptomatic leiomyomas that demand treatment. One
hundred thirty-seven of them were eligible and were recruited
to the prospective study to undergo either UAE or
hysterectomy. Fifty-seven patients of participants were
randomised. The rest 80 patients who refused to be randomised
were prospectively followed up as the randomised ones. Finally,
UAE was performed altogether for 86 patients (26 randomised
and 60 prospectively followed up only).
A  flow  diagram  of  clinical  and  MRI  follow-up  protocol  is
shown in Figure 2. Table 2 demonstrates the study design and
patient flow for Studies I-IV. Those patients whose
preprocedural MRI was available were included in Study I.
Those patients who were treated with UAE and whose MRI
examinations were available were included in Studies III and IV.
Inclusion  and  exclusion  criteria  to  the  study  are  shown  in
Table 3. Symptoms had to be severe enough to warrant
consideration of hysterectomy.
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Figure 1
Patient flow in the recruitment and during the randomised study.
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Table 2
The study design
Table 3
Inclusion and exclusion criteria to the prospective study
Inclusion criteria Exclusion criteria
- treatment-requiring symptoms a - suspected genital tract malignancy
- imaging confirmed leiomyomas - adnexal pathological features
- agreeing to hysterectomy, if
necessary
- acute pelvic inflammatory disease
- viable pregnancy or fertility preservation
- uterovaginal prolapse requiring treatment
- incontinence requiring treatment
- leiomyoma suitable for hysteroscopic
myomectomy b
- renal impairment
- previous reactions to contrast media
- endometriosis requiring treatment c
- clinically suspected adenomyosis c
a Symptoms had to be severe enough to warrant consideration of hysterectomy.
b A single leiomyoma 5cm or less in size and with 50% protrusion into the uterine
cavity.
c Relative contraindications.
Study Study purpose Patients
(n)
Methods
Study I To evaluate the association of
symptoms with MRI findings
122 Symptom questionnaire,
preprocedural MRI
Study II To compare the clinical success
of UAE and hysterectomy for the
treatment of leiomyomas
57;
27 to UAE,
30 to hys
Randomised comparison
by intention to treat in
2-year follow-up
Study III To evaluate the role of
myometrial and leiomyoma
ischaemia in postprocedural
pain after UAE using MRI
62 UAE,
Preprocedural MRI,
24-hour follow-up MRI
Study IV To investigate the value of
preprocedural MRI measures in
predicting uterus and
leiomyoma size reduction after
UAE
52 UAE,
Preprocedural MRI,
6-month follow-up MRI
UAE, uterine artery embolisation. Hys, hysterectomy. MRI, magnetic resonance imaging.
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Figure 2
A flow diagram of clinical and magnetic resonance imaging follow-up.
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4.2 SYMPTOMS AND CLINICAL EVALUATION
The initial prospective evaluation of the patients included
medical  and  gynecological  history  and  examination  by  a
gynecologist, who interviewed the patients using a
questionnaire. The asked symptoms and their classification are
shown in Table 4. Transvaginal ultrasound, Pap smear and
endometrial sampling were performed. Complete blood count,
ferritin, haematocrit, follicle-stimulating hormone, and
oestrogen levels were determined.
For analyses, patients in Study I were divided into three
groups according to the symptoms reported: 1) patients with
menorrhagia alone; 2) patients with pressure symptoms alone;
and 3) patients with both menorrhagia and pressure symptoms.
Table 4
Structured questionnaire for registering the symptoms
Symptom Classification
Menstrual flow
Duration in days
Severitya no periods mild moderate severeb
The frequency of changing
sanitary protection
normal increasedc
A pressure feeling d none mild moderate severe
To the bladder none mild moderate severe
To the bowel none mild moderate severe
To the back none mild moderate severe
Increased urinary frequency d none mild moderate severe
Urinary stress incontinence d none mild moderate severe
Pain d
Dysmenorrhea none mild moderate severe
Non-menstrual related
lower abdominal pain
none mild moderate severe
a Moderate or severe indicates ‘menorrhagia’.
b Menstrual flow was defined as ‘severe’ when it prevented participation in
everyday activities, caused anemia, and extra large pads and/or tampons were
needed.
c Change was required at 1- to 2-hour intervals and both pads and tampons were
needed at night.
d Mild, moderate and severe indicates ‘yes’.
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4.3 MAGNETIC RESONANCE IMAGING
4.3.1 MRI Protocol
All MRI studies were performed with an identical protocol
at 1.5 T (Siemens Vision; Siemens Medical System, Erlangen,
Germany) using a phased-array body coil.
Imaging Technique for Anatomical Imaging (Studies I, II, III
and IV)
Transverse and sagittal T2-weighted turbo SE imaging
(TR/TE 3,600/138 [repetition time msec/echo time msec]; flip
angle 180°; echo train length 29; in-plane matrix 116×256; field of
view 350 cm; section thickness 6 mm; intersectional gap 1.5 mm)
without contrast agent, and transverse and sagittal T1-weighted
gradient-echo imaging (TR/TE 170/2.3; flip angle 70°; in-plane
matrix 172 × 256; field of view 300 cm; section thickness 6 mm
without intersectional gap) before and after contrast agent
injection were performed. Gadobutrol (Gadovist; Schering,
Berlin, Germany) was administered at 0.1 mmol/kg of body
weight. The injection was performed at 5 mL/s. Non-dynamic
imaging was initiated 1.5 minutes after contrast agent injection.
Imaging Technique to Obtain the T1 Relaxation Time (Study IV)
To obtain T1 relaxation time one slice at the mid-level of the
dominant leiomyoma (defined as a leiomyoma with largest
diameter) was imaged with inversion recovery (IR) pulse
sequences (TR/TE 7.7/4.2; flip angle 15°; in-plane matrix 128 ×
128; slice thickness 8 mm). Imaging was repeated 10 times with
variable inversion times (10, 100, 200, 300, 400, 500, 800, 1600,
3200, and 5000 msec).
4.3.2 MRI Analysis
All analyses were performed using the picture archiving and
communication system (PACS) with IDS5-software (Sectra,
Linköping, Sweden).
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4.3.2.1 Anatomical Analysis (Studies I, II, III and IV)
The number and volume of leiomyomas and uterine
diameters were determined from transverse and sagittal T2-
weighted images. A leiomyoma was defined as a clearly
distinguishable and well-circumscribed tumor of homogenously
decreased or variable heterogeneous SI compared with that of
the myometrium in T2-weighted images, depending on the type
of degeneration (Murase et al. 1999). Leiomyoma diameters were
measured in three planes and the volume was calculated using
the formula for a prolate ellipse. For each patient, the total
volume of all leiomyomas was calculated by summing the
individual leiomyoma volumes. The uterine diameters were
measured in three planes: the length and anteroposterior
diameters from sagittal images, and the transverse diameter
(width) from axial images.
The volume of the uterus was measured using sequential
transverse contrast-enhanced T1-weighted images. The borders
of the uterus were delineated, and the volume was calculated by
summing the area measurements of individual slices and
multiplying the summed areas by the slice thickness. This
resulted in a true three-dimensional volume of the uterus. The
volume of the uterine corpus was measured in the same manner
by excluding the cervix (Study III). The volume of the
myometrium was calculated by subtracting the volume of the
leiomyomas from the volume of the uterine corpus (Study III).
The other anatomical characteristics of leiomyomas and
uteri were determined from transverse and sagittal T2-weighted
images. Leiomyoma location was designated as the location of
the center of the leiomyoma. The submucosal leiomyomas were
classified according to the proportion of leiomyoma protruding
into the uterine cavity according to the European Society of
Gynecological Endoscopy Classification of Submucous Fibroids
(Wamsteker et al. 1993). Thus, the relationship of leiomyomas to
the uterine endometrium was classified into four categories: 1)
presence of submucosal leiomyoma largely (50%) protruding
into the uterine cavity (also including the pedunculated
submucosal leiomyomas); 2) presence of a leiomyoma <50%
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protruding into the uterine cavity (i.e. intramural leiomyoma
with minor submucosal component); 3) intramural or subserosal
leiomyomas only in contact with the junctional zone; or 4)
intramural or subserosal leiomyomas without contact with the
junctional zone. These categories are illustrated in Figure 3. The
junctional zone was defined as a hypointense ring beneath the
endometrium in T2-weighted images.
One radiologist performed the preinterventional MRI
analyses (Studies I, II, III). In Study IV assessment of volumes of
dominant leiomyomas and uteri from both pre- and follow-up
MRIs were performed by two radiologists.
Figure 3
Characterization of leiomyoma/endometrium relationship.
Preprocedural non-enhanced T2-weighted turbo spin echo MR images
from three patients. (a) In a transverse image obtained from the patient
with menorrhagia two small submucosal leiomyomas (arrows) largely
50%) protrude into the uterine cavity. (b) A sagittal image obtained
from the patient with increased urinary frequency shows an
intramural leiomyoma (asterisk) without contact in the junctional
zone. (c) A sagittal image obtained from the patient with a pressure
feeling on the bladder and mild menstrual flow shows a leiomyoma
(asterisk) protruding into the uterine cavity indicating minor (<50%)
submucosal component.
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4.3.2.2 Tissue Characterization Analysis (Studies I, III, and IV)
Enhancement and Degeneration of Leiomyomas on
Preprocedural MRI (Study I)
The percentage of enhanced tissue of all leiomyomas was
assessed visually from contrast-enhanced T1-weighted images
as shown in Figure  4. The presence of hemorrhagic
degeneration as a possible cause of abdominal pain was
registered. Hemorrhagic degeneration shows a peripheral or
diffuse high SI on T1-weighted images and variable SI with a
possible low SI rim on T2-weighted images (Kawakami et al.
1994, Murase et al. 1999).
Figure 4
Assessment of enhancement of leiomyomas. Enhanced T1-weighted
gradient-echo MR images illustrate the enhancement of leiomyomas in
three patients. A transverse (a) image shows intense (100%)
enhancement of the large single leiomyoma (asterisk), a sagittal (b)
image shows 80% enhancement of leiomyomas, and a transverse (c)
image 30% enhancement of large leiomyomas (asterisks).
Twenty-four Hour Postprocedural MRI Analysis: Myometrial
and Leiomyoma Ischaemia (Study III)
Contrast enhancement of leiomyomas and myometrium was
assessed visually from transverse and sagittal contrast enhanced
T1-weighted images. The presence of nonenhancing tissue (i.e.
ischaemic) was registered. First, the percentage of ischaemic
tissue in the dominant leiomyoma, in all leiomyomas, and in
myometrial tissue of the uterine corpus was estimated. In the
semi-quantitative analysis, the absolute volumes of ischaemic
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tissue (ml) in the myometrium, in the dominant leiomyoma, and
in all leiomyomas were calculated. Second, the severity of
myometrial ischaemia was graded into four categories: grade 1,
no ischaemia; grade 2, mild; grade 3, moderate; grade 4, severe.
The grading was based on the assessment of the extent of
ischaemia and the completeness of non-enhancement (Figure 5).
Furthermore, the extent of ischaemia in myometrial tissue was
classified into three categories: 1, in the junctional zone; 2,
exceeding the junctional zone; 3, up to the serosal surface.
To create uniform criteria for ischaemia evaluation, two
radiologists first analysed 30 postprocedural MRIs together.
Then both readers interpreted all postprocedural studies
independently, and the other repeated the procedure after 1
month. Both radiologists were blinded to the postprocedural
pain reports.
Figure 5
Grading of myometrial ischaemia by MRI. Postprocedural contrast
enhanced T1-weighted gradient-echo MR images illustrate the severity
of myometrial ischaemia. A sagittal (a) image with multiple
leiomyomas shows mild uterine ischaemia (arrow) extending to the
endometrium and to the junctional zone. The percentage of leiomyoma
ischaemia was estimated to be 98%, because of a small enhancing area
in one fibroid (arrowhead). A transverse (b) image shows moderate
myometrial ischaemia (arrow) with incomplete dominant leiomyoma
ischaemia (arrowheads). A sagittal (c) image shows severe myometrial
ischaemia (arrow) extending to the outer serosa with complete
leiomyoma ischaemia.
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Quantitative Preinterventional MRI Measures (Study IV)
To calculate the dominant leiomyoma-to-skeletal muscle SI-
ratio in T2-weighted gradient echo images, two regions of
interest (ROIs) were identified; on the cross-sectional area of the
dominant leiomyoma and on the iliac muscle (Figure  6). The
leiomyoma-to-skeletal muscle SI-ratio was calculated.
To calculate contrast-enhancement of the dominant
leiomyoma, a ROI identical to that shown in Figure  6 was
drawn on the transverse T1-weighted image before and after the
contrast agent injection. The percentage of contrast
enhancement was calculated.
To calculate T1 time of the dominant leiomyoma SI was
measured from the dominant leiomyoma in each IR image and
plotted versus the inversion time. Leiomyoma T1-time was
calculated using the data fitting procedure described by Fritz-
Hansen et al (Fritz-Hansen et al. 1998).
To determine intraobserver variation, the same radiologist
repeated the ROI drawing for a sample of 20 patients 6 months
later. To determine interobserver variation, another radiologist
performed image analysis and the ROI drawing of the same 20
patients.
Figure 6
Drawing of regions of interest. The image shows an example of two
typical ROIs drawn over the dominant leiomyoma (large ROI) and
skeletal muscle for calculating the dominant leiomyoma-to-skeletal
muscle SI-ratio.
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4.4 TREATMENTS
4.4.1 Uterine Artery Embolisation
For premedication oral paracetamol 1g per os and, when
needed, diazepam 10 mg for sedation was given. Antibiotic
prophylaxis was administered before the procedure with one
dose of 1.5 g intravenous cefuroxime natrium and 500 mg
metronidazole. After UAE, oral cephalexin monohydras with a
dose of 500 mg x 3 and metronidazole with a dose of 400 mg x 2
were started for 5 days. The right femoral artery was accessed
with a 5-French introducer sheath under local anaesthesia. A
dose of 5000 IU heparin was given in the beginning of the
intervention. Digital subtraction angiography of the
contralateral internal iliac artery and selective study of the
anterior arterial branch was performed with a 4-French
diagnostic catheter (Glidecath Cobra, Terumo, Tokyo, Japan) to
determine the anatomy of the uterine artery (Figure 7).
Figure 7
Selective angiography of uterine arteries. Two angiographic images
obtained during the initial selective (a) right and (b) left uterine
arteriography show the supply of a large leiomyoma.
Uterine arteriography obtained before embolisation was
carefully evaluated with special attention given to the presence
of utero-ovarian anastomoses. The catheter was subsequently
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advanced into the horizontal portion of the uterine artery. The
ipsilateral internal iliac and uterine arteries were then accessed
with the same catheter. In tortuous, small, or spastic uterine
arteries, catheterisation was performed with a 2.1-French
microcatheter to ensure free-flow embolisation. Embolisation
was performed by calibrated microsphere particles (550–700
μm; EmboSphere; BioSphere Medical, Louvres, France) in all
interventions. The intention was to stop the embolisation when
the leiomyoma blood supply is occluded and the flow in the
peripheral portion of uterine artery is blocked but there was still
sluggish flow in the ascending segment of the uterine artery
observed (near-stasis) (Figures 8 and 9).
Figure 8
Angiographic images from a patient with one large leiomyoma. (a)
Selective right uterine arteriography shows the supply of the large
leiomyoma. Images (b) and (c) show the left uterine artery before and
after the embolisation. The last image (d) illustrates no supply to the
large leiomyoma in the aortography after UAE.
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Figure 9
Excellent response to UAE on MRI. (a) Preprocedural contrast
enhanced T1-weighted gradient-echo MR image of the same patient
than in Figure 8 illustrates the large leiomyoma (asterisk) with intense
enhancement (b) The large leiomyoma is not visible on a 3-year follow-
up MR image indicating an excellent response to UAE.
Further, abdominal aortography was performed if there was
suspicion of significant additional leiomyoma vasculature from
the ovarian artery (Figures 10 and 11).
Closure device was routinely used. The same experienced
interventional radiologist performed all interventions. During
the prolonged intervention intravenous fentanyl 25-50mg for
analgesia was given, if needed. In addition, nearly without
exception after the intervention prophylactic fentanyl was given
before transferring to a recovery room for 4–6 h, after which the
patients were transferred to the gynecology ward for further
care.
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Figure 10
Anatomical variant. (a) Angiography demonstrates a missing left
uterine artery. (b) The left ovarian artery (arrow) originates from the
left renal artery and supplies the uterus. (c) Angiography after the
embolisation shows patent left ovarian artery. (d) Selective
angiography demonstrates normal anatomy of the right uterine artery.
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Figure 11
MRI images before and after UAE. (a) Preprocedural contrast
enhanced T1-weighted gradient-echo MR image obtained from the
same patient than in Figure 10 shows partly degenerated leiomyoma
(asterisk) in the anterior part of the uterus. (b) Postprocedural non-
enhanced T2-weighted turbo spin echo and (c) enhanced T1-weighted
gradient-echo MR images after 3-year follow-up illustrate that the
leiomyoma (asterisk) shows no enhancement while adenomyosis
(arrow) in the posterior part of the uterus has maintained viable.
4.4.2 Postprocedural Pain and Pain Medication after UAE
(Study III)
Postprocedural pain intensity was assessed using the verbal
rating scale (VRS) (Williamson et al. 2005). The scale ranged
from 0 (no pain) to 10 (worst pain imaginable). In-hospital
subjective maximal pain levels were assessed at four different
times: (1) before leaving the angiography laboratory, (2) in the
recovery room, (3) in the gynecology ward and (4) 24 h after
UAE. For further analyses, the highest value from among these
VRS recordings was registered as the maximal in-hospital pain,
and the pain score was classified based on three categories: 1–3,
mild; 4–6, moderate; 7–10, severe.
Pain control during the immediate postprocedural recovery
period in the recovery room and on the ward was accomplished
with ibuprofen and oxycodone. For non-controllable pain, the
patient controlled analgesia pump was used. Ibuprofen 800 mg
x 3 for one week was started immediately after the procedure.
When ibuprofen was contraindicated, paracetamol was given
instead.
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4.4.3 Hysterectomy
The type of hysterectomy (abdominal, vaginal, or
laparoscopic-assisted) were not standardised and left to the
discretion of the attending gynecologist, in order to maintain the
protocol  as  close  to  that  of  daily  practice  as  possible.  General
anaesthesia was used in all operations.
4.4.4 Technical Success and Complications
The technical success of UAE and complications of
treatment were defined according to the SIR and CIRSE
guidelines (Goodwin et al. 2003, Hovsepian et al. 2009, Stokes et
al. 2010). The technical success was defined as occlusion or
marked reduction in blood flow in both uterine arteries.
Hysterectomies were defined as technically successful if they
were performed as planned.
Complications were stratified on the basis of outcome. Major
complications resulted in admission to hospital for therapy, an
unplanned increase in the level of care, prolonged
hospitalisation, permanent adverse sequelae or death; minor
complications resulted in no additional interventions and
required no therapy or at most nominal therapy or overnight
hospital stay for observation only.
4.4.5 Recovery
All UAE patients routinely stayed in hospital overnight.
They were discharged when there was no longer a need for
opiate medication. Periods of sick leave were changed after the
first experiences from 3 to 7–10 days.
After hysterectomy the patients were discharged when they
could urinate and neither infectious process nor intestinal
paralysis occured. Sick leave varied between 3 and 5 weeks.
Patients of both groups were encouraged to return to normal life
as soon as possible, and they were advised equally to contact the
gynecology emergency clinic if any problems appeared.
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4.4.6 Two-year Follow-up
The same questionnaire concerning symptom characteristics
completed at baseline was administered at each follow-up visit.
In addition, overall relief of symptoms, changes in menstrual
flow, and changes in pressure symptoms compared with
baseline were recorded using the following scale: symptom-free,
improved, unchanged, or worse; with symptom-free or
improved indicating improvement. The measures also included
the global health status with the Medical Outcome Study Short
Form 36 (SF-36) (Ware et al. 1992) at each follow-up visit.
Clinical success was defined according to SIR and CIRSE
guidelines as the resolution of presenting symptoms , such as
menorrhagia or bulk-related pain, bloating, urinary frequency,
or constipation, without additional therapy (Goodwin et al. 2003,
Hovsepian et al. 2009, Stokes et  al. 2010). Any additional
interventions required were recorded.
Satisfaction with treatment was evaluated by asking the
patients whether they would choose the performed treatment
again at each follow-up visit.
4.5 STATISTICAL ANALYSES
In general, continuous variables were tested for normal
distribution with the Kolmagorov-Smirnov 1-sample test. The
Student’s t-test was used to compare normally distributed data
and Mann–Whitney U test was used to compare nonparametric,
continuous-scale data for non-normally distributed variables
(Studies I, II and III). The Pearson Chi-Squared test and Fisher’s
exact analysis were used for categorical data and dichotomized
variables (Studies I, II, and III).
Student’s t-test, Mann-Whitney U-test, Pearson’s chi-
squared test, and Fisher’s exact test were used to analyze
differences in MRI derived leiomyoma and uterine
characteristics with respect to three symptom groups (Study I).
In further analyses, the same tests were used to find differences
in MRI findings with respect to the presence or absence of
45
specific pressure and pain symptoms; i.e. increased urinary
frequency, urinary stress incontinence, a feeling of pressure on
the bowel or back, and non-menstrual related lower abdominal
pain (Study I).
In univariate analyses, MRI variables reaching probability
(P) values less than 0.05 were included in the stepwise multiple
logistic regression analyses (Study I). The correlation between
the percentage of enhancement of leiomyomas and the size
measures of uteri and leiomyomas were assessed with the
Spearman’s rank correlation coefficient (Study I).
Randomised comparisons of UAE and hysterectomy were
performed according to intention to treat (i.e. the analysis
considers all randomly assigned patients in their primary
assigned groups), and per protocol (i.e. the analysis considers
only patients who completed the entire trial receiving the
intended treatment) (Study II). For patients who had withdrawn
or undergone secondary treatment before the follow-up analysis
was performed by taking the last valid observation carried
forward (Study II).
Correlation between continuous-scale variables were
assessed with the Spearman rank correlation coefficient, and the
Kruskal–Wallis test was used to compare continuous-scale
variables with respect to categorical variables (Study IV).
Correlations that were significant in univariate analyses were
further examined in multiple linear regression analyses. In
multivariate analyses the multicollinearity of variables was
excluded by using collinearity diagnostics (Study IV).
Intra- and interobserver repeatability of the assessments
were estimated by calculating kappa coefficients with 95%
confidence intervals (CI), and by calculating the intraclass
correlation coefficients, the coefficient of variation (Studies III
and IV).
A two-tailed P value of less than 0.05 was considered
statistically significant. All statistical analyses were performed
using SPSS software (SPSS for Windows, Chicago, IL, USA,
versions 11.5.1 - 17.0).
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5 Results
5.1 CLINICAL CHARACTERISTICS OF THE PATIENTS
The clinical characteristics of the 122 study patients (Study I)
are presented in Table 5. A total of 69 (57%) of the 122 women
(mean age, 47.5 years; range, 38–60) presented with both
menorrhagia and pressure symptoms, while around one-fifth
suffered either from menorrhagia alone (n=26 [21%]) or pressure
symptoms alone (n=27 [22%]).
Thirteen patients were postmenopausal; 12 of them were
receiving hormone replacement therapy, five had menorrhagia,
and 12 had pressure symptoms. Thirty patients (32%) with
menorrhagia had levonorgestrel releasing intrauterine system
(LNG-IUS) without releasing the bleeding symptom. Patients
with menorrhagia alone had significantly smaller uteri
(measured by bimanual palpation of ‘gestational week’ size)
compared to the other groups (mean 11.2 ± standard deviation
(SD) 3.6 [range, 6-22] versus 13.2 ± 2.2 [10-18] and 13.2 ± 3.5 [9-
24]).
In Study II the randomly assigned groups were comparable
in terms of baseline demographic data, clinical characteristics,
symptom severity, and preinterventional MRI findings. None of
the randomised patients had MRI features leading to exclusion
from the study.
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Table 5
Patient characteristics and symptoms at baseline (Study I)
Clinical characteristic Patients (n=122)
Age, yrs 47.5 ± 4.3 (38-60)
Postmenopausal a 13 (11)
Body mass index 26.5 ± 4.7 (18-44)
Uterus size b 12.8 ± 3.4 (6-24)
Levonorgestrel-releasing intrauterine system a 37 (30)
Menorrhagia a 95 (78)
Duration of menstrual flow, days 6.1 ± 2.9 (0-16)
Hemoglobin level, g/L 128 ± 17.1 (67-152)
Anaemia a 41 (34)
Acyclic bleeding a 31 (25)
Pressure symptoms a 96 (79)
Increased urinary frequency a 68 (56)
Urinary stress incontinence a 23 (19)
Pain a
Dysmenorrhea 46 (38)
Lower abdominal pain 50 (41)
Values are mean ± SD (range) unless otherwise specified.
a Values are n (%).
b Assessed by bimanual palpation as ‘gestational week’ size.
5.2 ASSOCIATION BETWEEN PREINTERVENTIONAL MRI
CHARACTERISTICS AND SYMPTOMS (STUDY I)
5.2.1 Differences in MRI Characteristics According to
Symptom Group (Table 6)
Patients with Menorrhagia alone versus those with Pressure
Symptoms alone
Leiomyoma with 50% protrusion into the uterine cavity
was detected in up to 39% of the MRI scans performed on
patients with menorrhagia alone, but only in 4% of patients with
pressure symptoms alone. Further, the mean percentage of
enhanced tissue of leiomyomas was greater in patients with
menorrhagia than in those with pressure symptoms. The mean
leiomyoma volume and mean uterine width was significantly
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smaller in patients with menorrhagia than in those with
pressure symptoms.
Patients with Menorrhagia alone versus those with both
Menorrhagia and Pressure Symptoms
The mean leiomyoma volume was two times larger and the
mean anteroposterior diameter and uterine width were
significantly greater in patients suffering from both
menorrhagia and pressure symptoms compared to those
suffering from menorrhagia alone. The mean percentage of
enhanced tissue of leiomyomas was significantly greater in
patients with menorrhagia alone than in those with both
symptoms.  The  volume  of  leiomyomas  was  an  independent
determinant for distinguishing the two groups in the multiple
logistic regression analysis (P=0.009).
Patients with Pressure Symptoms alone versus those with both
Menorrhagia and Pressure Symptoms
The only significant difference in MRI characteristics
between patients with pressure symptoms alone and those with
both symptoms was that leiomyomas with 50% protrusion into
the cavity were detected significantly more often in patients
with both symptoms.
Three of the patients with only menorrhagia and four of the
patients with both symptoms had no submucosal component in
any of their leiomyomas; one of them had adenomyosis on MRI,
one had a large hemorrhagic leiomyoma, and all of them had 75-
100% enhancement in leiomyomas. MRI identified one
suspected malignancy, but laparotomy revealed it to be a benign
leiomyoma. Adenomyosis was not diagnosed in any patient by
transvaginal US but it was detected on MRI in 9 patients, with
no differences in the frequency between the three symptom
groups. Only two of 122 patients had hemorrhagic degeneration
on MRI. Both of them reported non-menstrual related lower
abdominal pain and menorrhagia. The percentage of
enhancement of leiomyomas correlated inversely with the size
measures of uteri and leiomyomas (-0.307  r  -0.477; P<0.001).
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5.2.2. MRI Characteristics in Patients with Specific Pressure
and Pain Symptoms
In further analyses, differences in MRI findings were
evaluated and the patients were categorized with respect to the
presence or absence of each individual pressure and pain
symptoms. Table 7 demonstrates the significant MRI
characteristics that distinguish symptomatic patients from non-
symptomatic patients with respect to increased urinary
frequency, stress incontinence, lower abdominal pain, and a
feeling of pressure on the bowel and back. The table shows that
MRI measures of uterine and leiomyoma size, and the low
degree of enhancement in leiomyoma tissue, were all
significantly associated with increased urinary frequency. The
length of the uterus proved to be an independent determinant
for increased urinary frequency in multiple logistic regression
analysis (P=0.021).
The number of leiomyomas, the relationship of leiomyomas
to the endometrium, and the presence of hemorrhagic
degeneration or adenomyosis were not associated with any
specific pressure or pain symptoms. Further, none of the MRI
characteristics were associated with urinary stress incontinence,
with non-menstrual related-pain in the lower abdomen, or with
a feeling of pressure on the back.
52
Ta
bl
e 
7
A
ss
oc
ia
tio
n 
be
tw
ee
n 
m
ag
ne
tic
 re
so
na
nc
e i
m
ag
in
g 
ch
ar
ac
te
ri
st
ic
s a
nd
 sp
ec
ifi
c p
re
ss
ur
e a
nd
 p
ai
n 
sy
m
pt
om
s
S
y
m
p
to
m
M
a
g
n
e
ti
c 
re
s
o
n
a
n
ce
 i
m
a
g
in
g
ch
a
ra
ct
e
ri
st
ic
 a
In
cr
e
a
se
d
 u
ri
n
a
ry
fr
e
q
u
e
n
cy
(n
=
6
8
 v
s 
n
=
5
4
)
S
tr
e
s
s
in
co
n
ti
n
e
n
ce
(n
=
2
3
 v
s 
n
=
9
9
)
L
o
w
e
r 
a
b
d
o
m
in
a
l
p
a
in
(n
=
5
0
 v
s 
n
=
7
2
)
P
re
ss
u
re
 f
e
e
li
n
g
to
 b
o
w
e
l
(n
=
2
7
 v
s 
n
=
9
5
)
P
re
ss
u
re
 f
e
e
li
n
g
to
 b
a
ck
(n
=
2
5
 v
s 
n
=
9
7
)
M
ea
n
 v
o
lu
m
e 
o
f 
le
io
m
yo
m
a
s 
(m
l)
 
2
3
9
 v
s 
1
7
8
,
P
=
0
.0
0
2
1
9
9
 v
s 
2
1
5
,
P
=
0
.7
1
6
1
9
8
 v
s 
2
2
2
,
P
=
0
.8
0
3
2
9
1
 v
s 
1
9
0
,
P
=
0
.5
8
9
2
2
3
 v
s 
2
0
9
,
P
=
0
.5
9
2
M
ea
n
 u
te
ru
s 
le
n
g
th
 (
m
m
)
1
2
2
 v
s 
1
1
0
,
P
=
0
.0
3
2
1
1
7
 v
s 
1
1
6
,
P
=
0
.9
1
9
1
1
4
 v
s 
1
1
8
,
P
=
0
.5
1
0
1
1
2
 v
s 
1
1
8
,
P
=
0
.4
1
9
1
1
2
 v
s 
1
1
7
,
P
=
0
.2
3
6
M
ea
n
 u
te
ru
s 
a
p
-d
ia
m
et
er
 (
m
m
)
9
2
 v
s 
8
3
,
P
=
0
.0
0
5
8
9
 v
s 
8
8
,
P
=
0
.9
6
1
8
6
 v
s 
8
9
,
P
=
0
.5
2
7
9
5
 v
s 
8
6
,
P
=
0
.2
1
7
9
2
 v
s 
8
7
,
P
=
0
.3
1
8
M
ea
n
 u
te
ru
s 
w
id
th
 (
m
m
)
9
7
 v
s 
9
0
,
P
=
0
.0
1
1
9
3
 v
s 
9
4
,
P
=
0
.8
0
6
9
1
 v
s 
9
6
,
P
=
0
.3
1
0
9
9
 v
s 
9
3
,
P
=
0
.5
3
1
9
4
 v
s 
9
4
,
P
=
0
.8
0
9
M
ea
n
 u
te
ru
s 
vo
lu
m
e 
(m
l)
5
2
4
 v
s 
4
1
5
,
P
=
0
.0
0
3
4
7
0
 v
s 
4
7
7
,
P
=
0
.6
5
1
4
4
6
 v
s 
4
9
7
,
P
=
0
.6
3
5
5
5
1
 v
s 
4
5
5
,
P
=
0
.8
2
5
4
9
6
 v
s 
4
7
1
,
P
=
0
.7
3
1
M
ea
n
 p
er
ce
n
ta
g
e
 o
f 
en
h
a
n
ce
d
ti
ss
u
e
 o
f 
le
io
m
yo
m
a
s
8
6
.8
 v
s 
8
8
.1
,
P
=
0
.0
2
2
9
2
.0
 v
s 
8
6
.3
,
P
=
0
.2
4
2
8
6
.6
 v
s 
8
7
.9
,
P
=
0
.5
9
2
8
4
.5
 v
s 
8
8
.2
,
P
=
0
.0
4
9
8
7
.2
 v
s 
8
7
.4
,
P
=
0
.4
5
1
a
 O
n
ly
 s
ig
n
if
ic
a
n
t 
m
ag
n
et
ic
 r
e
so
n
a
n
ce
 i
m
a
g
in
g
 c
h
a
ra
ct
er
is
ti
cs
 t
h
a
t 
d
is
ti
n
g
u
is
h
 s
ym
p
to
m
a
ti
c 
p
at
ie
n
ts
 f
ro
m
 n
o
n
-s
y
m
p
to
m
a
ti
c 
p
at
ie
n
ts
 w
it
h
 r
es
p
ec
t 
to
sp
e
ci
fi
c 
p
re
ss
u
re
 a
n
d
 p
ai
n
 s
ym
p
to
m
s.
53
5.3 COMPARISON OF UAE AND HYSTERECTOMY BY
INTENTION-TO-TREAT (STUDY II)
5.3.1 Technical Success and Complications
Technical success of the treatments performed was 25/27
(93%) in the UAE group and 21/26 (81%) in the hysterectomy
group  (P=0.204). Two (7%) of the UAE patients received
unilateral UAE because of a hypoplastic left uterine artery. One
crossover patient from the UAE group underwent vaginal
hysterectomy successfully. Procedures in the hysterectomy
group included 16 (61%) abdominal hysterectomies, 7 (27%)
vaginal hysterectomies and 3 (12%) laparoscopic-assisted
vaginal hysterectomies. In the hysterectomy group, 5/26 (19%)
vaginal or laparoscopic hysterectomies were converted to
abdominal hysterectomy owing to technical difficulties.
None of the UAE patients but two hysterectomy patients
(7%) encountered major complications (P=0.492); one
relaparotomy because of urinary bladder lesion, and one patient
encountered postoperative haematoma and infection. One UAE
patient encountered a groin haematoma that required no
specific treatment.
5.3.2 Recovery
Recovery was faster in the UAE group than in the
hysterectomy group. Mean length of sick leave was significantly
shorter after UAE than after hysterectomy (10.8 days versus 34.9
days; P=0.001). Patients discharged from hospital significantly
earlier after UAE than after hysterectomy (mean 1.3 days versus
3.5 days; P=0.001).
5.3.3 Two-year Follow-up Results
5.3.3.1 Improvement of Symptoms
The improvement of symptoms during the 2-year period is
presented in Figure 12. Overall relief of symptoms was good in
both groups; 22 (82%) of the UAE patients and 28 (93%) of the
hysterectomy patients reported total or substantial relief of
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symptoms. Among patients with menorrhagia, 12/18 (67%) had
total or substantial improvement after UAE. Among patients
with pressure symptoms, total or substantial improvement was
reported significantly more often by patients in the UAE group
than by patients in the hysterectomy group (19/20 [95%] versus
18/26 [69%]. There was more urinary bladder symptoms after
hysterectomy than after UAE (9 [30%] versus 2 [7%]; P=0.031).
Occurrence of urinary stress incontinence was even increased
among hysterectomy patients being 13 [43%] versus 7 among
[26%] UAE patients (P=0.169).
Figure 12
Total or substantial improvement of symptoms after UAE and
hysterectomy at 2-year follow-up. Data analyzed by intention-to-treat
show that significantly better improvement of menorrhagia was
reported by hysterectomy patients while significantly better
improvement of pressure symptoms was reported by UAE patients, but
there was no difference in overall improvement of symptoms.
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5.3.3.2 Clinical Success and Additional Treatments
A clinical success rate of 81% was registered in the UAE
group compared with 90% in the hysterectomy group (P=0.238).
Five of the 27 patients (19%) in the UAE group required an
additional invasive procedure during the follow-up: three
hysteroscopies and 3 hysterectomies for continued bleeding or
pain. Thus, the rate of secondary hysterectomies at 2 years was
12%.
Three of the 30 patients (10%) in the hysterectomy group
required additional treatment because of continuing symptoms;
laparotomy for pain, and hysteroscopic myomectomy or
insertion of  LNG-IUS was performed for two of four primarily
untreated patients because of bleeding symptoms.
5.3.3.3 Satisfaction to the Treatment
The majority of patients would have chosen their performed
treatment again in both groups after two years: 24 [89%]
patients in the UAE group versus 29 [97%] patients in the
hysterectomy group (P=0.336).
The aforementioned results were calculated by using per
protocol analysis as well. There was a trend towards better
results in the UAE group concerning pressure relief on the
urinary bladder and improvement of pressure symptoms at 2
years but these differences were not statistically significant
(p=0.123 and p=0.477, respectively). Otherwise, per protocol
analysis demonstrated no substantial differences compared with
the results reported above.
5.4 POSTPROCEDURAL PAIN AFTER UAE AND MYOMETRIAL
AND LEIOMYOMA ISCHAEMIA ON 24 H MRI (STUDY III)
The mean volume of embolisation agent used was 6 ml
(median, 6 ml; range, 2–18 ml). In 27 patients (44%) the endpoint
of embolisation was stasis of both uterine arteries; in the
remainder of patients, either one (29 patients) or both uterine
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arteries (5 patients) were embolised only to near-stasis. For one
patient the endpoint was not recorded.
5.4.1 Postprocedural Pain
The mean maximal in-hospital VRS value was 7.7 (median,
8.0; range, 1–10); the maximal pain was severe in 46 patients,
moderate in 11 patients and mild in 5 patients.
The mean maximal pain score was 4.2 in the angiography
laboratory right after UAE and 7.5 in the recovery room, i.e. 1–6
h after embolisation, where 54 patients (87%) reported their
highest pain score. The pain level diminished gradually, and the
mean maximal pain score was on the ward 5.1 and at the time of
the follow-up MRI, about 24 h after UAE, 1.9. At that time, 44
patients (71%) reported only mild residual pain.
5.4.2 Ischaemia on MRI
In MRI analysis severe or moderate myometrial ischaemia
that exceeded the junctional zone was in about one-half of the
patients. The mean percentage of ischaemic tissue in the
myometrium by two readers was 18%/20% and in leiomyoamas
92%/93%. The mean ischaemic volume assessed in the
myometrium was 35ml/38 ml, whereas the mean ischaemic
volume in the leiomyomas was 177ml/179 ml.
5.4.3 Determinants of Maximal In-hospital Postprocedural
Pain
The severity of myometrial ischaemia, the percentage and
volume of ischaemic tissue in the myometrium, and the volume
of embolisation agent significantly positively correlated with
severe maximal in-hospital pain (Figure 13). Patients with
moderate or severe myometrial ischaemia reported severe pain
more frequently than those with only mild myometrial
ischaemia (28/33 [85%] versus 18/29 [62%], P=0.041). The mean
percentage and the mean volume of ischaemic tissue in
myometrium were higher in patients who reported severe pain
than in those who reported only moderate or mild pain (mean
23% versus mean 11%, and mean 45 ml versus mean 20 ml).
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Patients embolised with more than 6 ml embolisation agent
reported severe pain more frequently than those embolised with
less than 6 ml (24/27 [89%] versus 22/35 [63%], P=0.038).
Figure 13
Determinants of maximal in-hospital postprocedural pain after UAE.
The bar graph shows that patients with moderate or severe myometrial
ischaemia reported severe pain more frequently than those with only
mild myometrial ischaemia (a). Patients embolised with more than 6
ml embolisation agent reported severe pain more frequently than those
embolised  with  less  than  6  ml  (b).  The  mean  percentage  (c)  and  the
mean volume (d) of ischaemic tissue in myometrium were higher in
patients who reported severe pain than in those who reported only
moderate or mild pain.
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The factors that showed no association with maximal in-
hospital pain were preinterventional volume of the uterine
corpus and of the leiomyomas, the end-point of embolisation
achieved, and leiomyoma ischaemia on the 24-h MRI.
5.4.4 Determinants of Ischaemia on MRI
When the endpoint was stasis in both uterine arteries (27
patients), the mean percentage of ischaemic tissue was
significantly higher in leiomyomas compared with patients in
whom both or one uterine artery was embolised only to near-
stasis (34 patients) (96% versus 89%, P=0.017). In addition, uteri
embolised with more than 6 ml of embolisation agent (27
patients) had larger volumes of ischaemic leiomyoma tissue
than those embolised with 6 ml or less (35 patients) (233 ml
versus 132 ml, P=0.023). Further, the use of a large volume of
embolisation agent (more than 6 ml) was associated with a large
leiomyoma volume (mean 259 ml versus 153 ml, P=0.031) and
with a large uterine corpus volume (519 ml versus 340 ml,
P=0.020) on preinterventional MRI. On the other hand, uteri
embolised with 6 ml or less of embolisation agent showed
severe or moderate myometrial ischaemia more frequently than
those embolised with more than 6 ml (23/35 [66%] versus 10/27
[37%], P=0.025). Further, patients with moderate or severe
myometrial ischaemia had a smaller uterine corpus (347 ml
versus 498 ml, P=0.008) than those with only mild ischaemia.
5.4.5 Repeatability of MRI Measurements
Intraobserver repeatability and interobserver reproducibility
of the evaluations of severity of myometrial ischaemia were
high (intra- and interrater  were 0.87 and 0.74, respectively).
The intra-and interrater  for assessing the extent of myometrial
ischaemia was 0.76 and 0.31 indicating lower interrater
repeatability. The intra- and interobserver repeatability were
moderate for percentage of ischaemic myometrial tissue (CV%
24% and 24%, respectively) and high for ischaemic leiomyoma
tissue (CV% 2% and 3%, respectively).
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5.5 PREDICTIVE VALUE OF MRI MEASURES IN UTERUS AND
DOMINANT LEIOMYOMA SIZE REDUCTIONS (STUDY IV)
5.5.1 Uterus and Dominant Leiomyoma Size Reductions after
UAE
During the 6-month follow-up after the UAE, both the
uterus and dominant leiomyoma sizes decreased in 49 patients
(94%). The mean uterus size reduction was 156 mL ± 131 (range,
-51-592 mL), where the minus sign indicates an enlargement,
and the mean dominant leiomyoma size reduction was 55 mL ±
66 (range, -82-257 mL). The percentages of uterus and dominant
leiomyoma size reductions were 33% ± 21 (range, -23-67%) and
44% ± 31 (range, -43-100%), respectively.
5.5.2 Correlation between Preinterventional MRI Measures
and Uterus and Dominant Leiomyoma Size Reduction
T1 time and leiomyoma-to-skeletal muscle T2 SI-ratio were
significantly positively correlated with both uterus (0.440 and
0.470, respectively) and leiomyoma (0.338 and 0.258,
respectively) size reductions assessed by Spearman’s rank
correlation analysis. The contrast enhancement, size, or location
of dominant leiomyoma was not associated with size
reductions.
5.5.3 Diagnostic Performance Predictions of Uterus and
Leiomyoma Size Reductions
Leiomyoma-to-skeletal muscle T2 SI-ratio, T1 time, and
contrast enhancement were useful MRI measures for predicting
uterus and leiomyoma size reductions. The highest accuracy for
the predictions was given by leiomyoma- to-skeletal muscle T2
SI-ratio to predict 75% leiomyoma size reductions (Az = 0.930;
95% CI: 0.853, 1.000). Table 8 summarizes the points on the
receiver operating characteristic (ROC) curve for each MRI
measure that were closest to the coordinates (0,1) for diagnosing
size reduction and the corresponding values of diagnostic
performance.
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High leiomyoma-to-skeletal muscle T2 SI-ratio and T1 time
had high sensitivities and specificities in identifying patients
with 50% or 75% leiomyoma size reductions. Further, high
leiomyoma-to-skeletal muscle T2 SI-ratio (Fig 14) had high
sensitivities and specificities in identifying patients that had
50% uterus size reductions.
Figure 14
Leiomyoma size reduction on MRI at 6-month follow-up. Sagittal
preprocedural T2-weighted image (a) demonstrates a relatively high SI
of the leiomyoma (leiomyoma-to-muscle T2 SI-ratio = 3.4). Six-month
follow-up image (b) shows that the leiomyoma had diminished by 63%.
Note there is no contact in the endometrium anymore (arrow).
5.5.4 Repeatability of MRI Measurements
In Study IV the T1 time measure had the least variation in
intra- and interobserver measurements (CV% 4% and 11%,
respectively). Intra- and interobserver repeatability for
leiomyoma-to-skeletal muscle T2 SI ratio (CV% 15% and 27%,
respectively) and for contrast enhancement (CV% 17% and 15%,
respectively) were lower.
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6 Discussion
In the present study, two treatments, UAE and
hysterectomy, for symptomatic patients with uterine
leiomyomas were prospectively compared at mid-term follow-
up. New aspects of the use of MRI to evaluate the association of
various symptoms and imaging findings of uterine leiomyomas,
to assess the leiomyoma and myometrial ischaemia after UAE in
considering the postprocedural pain, and to predict the uterine
and leiomyoma size reduction after UAE, were sought.
6.1 ASSOCIATIONS BETWEEN PATIENT SYMPTOMS AND MRI
FINDINGS (STUDY I)
The Study I utilizes the excellent anatomical visualization of
uterine leiomyomas by MRI to study the association between
patient’s symptoms and MRI characteristics of leiomyomas.
Menorrhagia and Relationship of Leiomyomas to Endometrium
It has been a common clinical suggestion that a submucosal
leiomyoma is strongly associated with menorrhagia. Our
analysis showed that the degree of submucosal extension has an
influence on menorrhagia. Indeed, the proportion of women
having submucosal leiomyomas with 50% protrusion into the
uterine cavity was significantly greater among patients with
menorrhagia compared to those without menorrhagia. In
addition, a minor submucosal component protruding into the
cavity had no implication for the bleeding symptom.
MRI is an ideal tool for evaluating the characteristics of large
uterine leiomyomas, especially the leiomyoma location and
submucosal leiomyoma extent (Dueholm et  al. 2001, Spielmann
et al. 2006). In previous MRI studies the results concerning the
relationship between menorrhagia and leiomyoma location have
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been controversial. One MRI study with 23 patients showed that
leiomyomas associated with hypermenorrhea anatomically
disrupted the junctional zone (Hricak et  al. 1986). Further,
Sulaiman et al. found in a retrospective study that menstrual
blood loss was associated with a submucosal location on MRI
(Sulaiman et  al. 2004). On the other hand, one study that
prospectively followed 46 patients by MRI reported that a
submucosal location was not associated with leiomyoma related
symptoms (Arleo et al. 2007). Previous US studies have also
shown mixed results. Similar to our findings, one cross-sectional
US study of non-care-seeking women showed that the tissue
layer location of leiomyomas was related to menstrual cycle
characteristics (Marino et  al. 2004). Another prospective
ultrasound study of 80 patients with abnormal bleeding found
that an intramural location was also associated with increased
bleeding complaints (Clevenger-Hoeft et al. 1999). In contrast, in
a study of a random sample of women, the risk for heavy
menstrual bleeding was not related to leiomyoma location
(Wegienka et al. 2003).
However, in the present study seven patients with
menorrhagia had no submucosal component in their
leiomyomas. There must also be another mechanism that leads
to heavy bleeding. In fact, according to a review article of Osei et
al. there are women who suffer from heavy bleeding without
apparent uterine pathology (Osei et al. 2005).
Enhancement of Leiomyomas
One of our study aims was to clarify the possible association
of enhancement in leiomyomas with symptoms. This issue has
not been evaluated before. We used a similar visual analysis of
the percentage enhancement of leiomyomas as we did for
analysing nonenhancement of leiomyomas after UAE (Study
III). The leiomyomas of the patients suffering from menorrhagia
showed a significantly higher degree of enhancement than the
leiomyomas of the patients with pressure symptoms. In other
words, intense enhancement of leiomyomas may contribute to
heavy bleeding. On the other hand, although the enhancement
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of leiomyomas correlated inversely with leiomyoma size, it was
not an independent determinant in the multiple logistic
regression analysis.
Size Measures of Uteri and Leiomyomas
As expected, the sizes of uteri and leiomyomas among
patients with pressure symptoms were significantly greater than
among those without, thus leiomyomas were smaller among
patients with only menorrhagia.
Association of MRI Characteristics with Increased Urinary
Frequency, Stress Incontinence, Lower Abdominal Pain, and
Feeling of Pressure on the Bowel and Back
Pressure complaints are a heterogenous group of various
symptoms and the term ‘pressure symptom’ is sometimes
difficult to interpret; patients suffer from the feeling of
uncomfortable pressure in their pelvic region. Most studies have
evaluated only a few symptoms and mainly the volume of the
largest leiomyoma, instead of the volume of all leiomyomas, has
been used. The results showed that increased urinary frequency
seems to be associated with large leiomyomas and uteri. Indeed,
in the Ontario trial the urinary frequency and urgency were
greatly or moderately improved in 68% of 306 women following
a mean 35% volume reduction in a leiomyomata uterus after
UAE, indicating that leiomyomas are truly associated with
urinary symptoms (Pron et  al. 2003c). In contrast to our results,
another prospective MRI study found that the total uterine
volume was not associated with leiomyoma-related symptoms
(Arleo et al. 2007).
A study by Murase et al. implied that hemorrhagic
degeneration in particular may be concurrent with pain
symptoms (Murase et al. 1999). We found hemorrhagic
degeneration by MRI in only two of our patients, both of whom
reported non-menstrual related lower abdominal pain. Thus, the
number of patients with this type of degeneration was too small
to warrant any conclusions about the relationship between
hemorrhagic degeneration and symptoms.
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Symptoms not Associated with MRI Characteristics
It has been suggested that a large number of leiomyomas is
associated with symptom severity (Buttram et  al. 1981,
Vollenhoven et al. 1990). Our findings do not support this as the
number of leiomyomas was not associated with any symptom.
While various patient complaints are often attributed to
leiomyomas, it is probable that not all pressure and pain
symptoms are leiomyoma-related. In our study, urinary stress
incontinence, non-menstrual related lower abdomen pain, and a
feeling of pressure on the back were not associated with any
MRI characteristics. Therefore, further investigation to exclude
other etiologies such as in the case of urinary stress incontinence
and in the case of abdominal pain, may be prudent. We agree
with the conclusions by Hutchins that other predisposing
factors should be considered in patients with leiomyomas and
chronic  pelvic  pain  (Hutchins  1995).  This  is  also  supported  by
the findings in a population-based ultrasound study of non-
care-seeking patients where the occurrence of pelvic pain had
no correlation with leiomyoma volume or number (Lippman et
al. 2003).
Preprocedural MRI could help detect other possible causes
of pain or pressure complaints, such as adenomyosis, pelvic
varices, endometriosis, pelvic inflammatory disease, or bowel-
or spine-associated causes. Actually, in our study population
there was no suspicion of adenomyosis by transvaginal US, but
adenomyosis was found by MRI in 7% of patients.
Strength and Limitations of Study I
Our patient population is larger than those in other studies
focusing on the association between MRI findings and
symptoms of leiomyomata patients. Further, none of the
consecutive patients was excluded due to any specific symptom.
It should be noted that the study group consisted of patients
with treatment demanding symptoms. In order to clarify a
general view of the association between MRI and clinical
characteristics of leiomyoma patients, symptom-free women
with leiomyomas should be included as a control group.
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Further, the reproducibility of the preinterventional MRI
assessment was not analyzed for Study I. However, previous
studies have shown that MRI assessment of uterine leiomyomas
has good inter- and intraobserver reproducibility (Dueholm et
al. 2002, Volkers et al. 2008b).
6.2 COMPARISON OF UAE AND HYSTERECTOMY (STUDY II)
Randomisation
Thus far, only three randomised trials comparing UAE and
hysterectomy have been carried out (Table 1): a Spanish
singlecenter trial (Pinto et  al. 2003), a multicenter REST trial in
the UK (Edwards et  al. 2007), and a multicenter EMMY trial in
the Netherlands (Volkers et  al. 2007). EMMY trial recently
published the 5-year outcome (van der Kooij et  al. 2010). In the
multicenter trials most individual centers have included only a
small number of patients resulting in a large number of
participating hospitals with heterogeneous technical
performance and previous experience with UAE, complicating
the interpretation and judgement of the general clinical
applicability of the results.
Our randomised sample size was small. Attempts to
randomise more patients in a reasonable time failed because of
difficulties in recruitment. During study period, of the patients
requiring treatment for leiomyomas, 26% were recruited to the
study, and 42% of eligible patients were randomised. Many of
our study patients refused to randomise and preferred UAE
(n=60) to avoid an invasive operation, and on the other hand,
many women preferred hysterectomy (n=18) as a definitive
treatment. Many aspects effect on the patients’ opinion on
severing their uteri including the cultural aspects in different
countries. Data from Nevadunsky suggested that many women
consider the uterus an important aspect of their feminity and
sexual image (Nevadunsky et al. 2001). Also, in the EMMY trial
only 51% of eligible patients agreed to be randomised and it
took 2 years to gather 177 patients from 28 participating
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hospitals (Hehenkamp et  al. 2005). REST investigators also had
difficulties in recruitment (Edwards et al. 2007). Despite the
small number of patients in our study groups, they were well
balanced concerning symptoms and MRI findings after
randomisation. In addition, one experienced interventional
radiologist performed all embolisations, providing a uniform
technique.
The strength of our trial is that the research population was
unselected; patients were not excluded according to the
presenting symptoms. Only one of the earlier randomised trials,
REST study (Edwards et  al. 2007), included both menorrhagia
and pressure symptoms in the inclusion criterias and there was
no limit on the size or number of leiomyomas, but there were a
large number of participating hospitals like in EMMY trial
(Volkers et al. 2007). In addition, EMMY trial excluded patients
with submucosal leiomyomas and patients who had exclusively
bulk-related symptoms and/ or pain but no menorrhagia. In the
study  by  Pinto  et  al.  (Pinto et  al. 2003), the inclusion criterion
also was menorrhagia only, and the patients with leiomyomas
larger than 10 cm in diameter were excluded.
Complications and Recovery
Our finding of a higher major complication rate with
hysterectomy (7%) than with UAE was not statistically
significant. In most previous studies a major complication rate
was higher in patients with hysterectomy (Dutton et al. 2007,
Edwards et  al. 2007, Pinto et  al. 2003, Spies et  al. 2004b). In
contrary, EMMY trial showed no statistically significant
differences between the treatment groups (Hehenkamp et  al.
2005). The explanation for these divergent results could be
variable inclusion criteria in the individual studies. Considering
the major complications after hysterectomy, laparoscopic and
vaginal hysterectomies have become more common during
recent years in Finland and the overall incidence of major
complications has decreased (Brummer et al. 2008).
In the present study patients in the UAE group recovered
faster than patients in the hysterectomy group, confirming the
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results of earlier studies (Edwards et al. 2007, Hehenkamp et al.
2006, Pinto et al. 2003, Spies et al. 2004b). There also is evidence
for shorter hospital stay and quicker return to work in other
mini-invasive treatment options such as magnetic resonance-
guided focused ultrasound, laparoscopic uterine artery
occlusion,  and  cryomyolysis  when  compared  to  hysterectomy
(Sharp 2006).
Two-year Follow-up Results
The results showed that UAE gave good overall relief of
symptoms, comparable to hysterectomy. In contrary, the REST
trial reported significantly better symptom scores in the surgical
group at one year (Edwards et al. 2007). Further, more women in
the hysterectomy cohort reported relief of leiomyoma symptoms
(89% versus 80%) and feeling better (81% versus 74%) in  a
multicenter retrospective HOPEFUL study (Dutton et al. 2007).
Of patients with menorrhagia in the UAE group,
improvement was reported by two-thirds in the present study.
This result is comparable with those of previous randomised
studies (Pinto et al. 2003, Volkers et al. 2007).
A new finding in the study was that significantly better
improvement of pressure symptoms was reported by UAE
patients. Thus, our findings imply that UAE is preferable to
hysterectomy in patients suffering from pressure symptoms. In
particular, there were significantly more pressure symptoms of
the bladder and more urinary stress incontinence after
hysterectomy than after UAE. Similarly, significantly more of
women reported worsening urinary symptoms after
hysterectomy (27%) than after UAE (8%) in HOPEFUL study
(Hirst et  al. 2008). Thus, it seems that the term “pressure
symptom” is unspecific and includes the possibility that other
causes than leiomyomas are the etiology of these symptoms. The
results of our Study I also implies that. In addition,
hysterectomy seems to increase the risk of urinary incontinence
(Altman et  al. 2007, Brooks et  al. 2009). On the other hand, in
EMMY trial there were no differences in improvement of bulk-
related symptoms between groups at 2-years (Volkers et  al.
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2007). However, in EMMY trial better improvement of
defecation function was found after UAE at 5-year follow-up
comparing to hysterectomy (van der Kooij et al. 2010).
Our  findings  indicated  that  UAE  was  not  inferior  to
hysterectomy considering patients’ satisfaction after two years.
This was in concordance with two other randomised trials
(Edwards et al. 2007, Pinto et al. 2003). Conversely, in the EMMY
trial the patients in the hysterectomy group were significantly
more satisfied after two years than those in the UAE group
(Hehenkamp et  al. 2008), but at 5-year follow-up there was no
difference (van der Kooij et al. 2010).
The trend in treatment for leiomyomas is toward a more
conservative approach (Jacobson et al. 2007). Jacobson et al.
evaluated data regarding uterine conserving procedures for the
treatment of leiomyomas (Jacobson et  al. 2007). The study was
based on the clinical database of women >20 years with
symptomatic leiomyomas from 1997 to 2003 in a Northern
California population. They noticed that during these years the
increase in rate of UAE had the greatest impact on treatment,
possibly replacing hysterectomy. However, they also reported
that rate of hysterectomy after initial uterine conserving
procedures reached 17.7% for UAE (Jacobson et al. 2007), being
in concordance with other trials and our study: two years after
UAE, 12% of patients had undergone a secondary hysterectomy.
This is equal to the finding in the REST (Edwards et al. 2007), but
a lower rate than that in the EMMY trial (Volkers et  al. 2007).
After 5 years the rate of hysterectomy after UAE was 28% in
EMMY trial, all because of uncontrolled menorrhagia (van der
Kooij et  al. 2010). Thus, the patients have to be informed that
heavy bleeding may be decreased but not eliminated completely
and there may be a need for an additional treatment. The total
need for additional interventions for symptom control after
UAE in our study was comparable with the results of EMMY
and REST trials (Edwards et al. 2007, Volkers et al. 2007).
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6.3  POSTPROCEDURAL  PAIN  AFTER  UAE  AND  UTERINE
ISCHAEMIA ON MRI (STUDY III)
In Study III, the extent and severity of uterine ischaemia on
MRI one-day post-procedure were used to evaluate the
association between the severity of postprocedural pain and
myometrial and leiomyoma ischaemia after UAE. Although
findings from several MRI follow-up studies have shown that
myometrial perfusion recovers (Banovac et al. 2002, deSouza et
al. 2002, Jha et al. 2000, Katsumori et al. 2001, Pelage et al. 2000),
even then, transient myometrial ischaemia can be an important
clinical issue because it can contribute to postprocedural pain
following UAE (Sterling et al. 2002).
Determinants of Postprocedural Pain
Our results show the importance of myometrial ischaemia in
the pathophysiology of frequent, often severe postprocedural
pain. Indeed, severe maximal inhospital pain correlated
positively with myometrial ischaemia, but not with leiomyoma
ischaemia. Although uterine ischaemia was detected in all
patients by MRI, only about 20% of the myometrial tissue was
ischaemic, while about 90% of leiomyoma tissue was ischaemic.
These data indicate that leiomyoma tissue is more vulnerable to
embolisation than the myometrium. Scheurig-Muenkler et al.
also showed that complete reperfusion of myometrial tissue is
observed with 48-72 hours after UAE possible due to the rich
collateral supply in the pelvis (Scheurig-Muenkler et  al. 2010).
Further, the vasculature of the leiomyoma tissue may be
different from that of the myometrium as suggested by the
gradual reversal of myometrial ischaemia. It is likely that at the
time of maximum postprocedural pain, the myometrial
ischaemia was most severe, while leiomyoma ischaemia was
complete and mainly irreversible.
The use of a large volume of embolic agent was associated
with severe postprocedural pain. Volkers et al. also
demonstrated a distinct correlation between high pain scores
and the amount of PVA particles (Volkers et al. 2006).
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The finding that postprocedural pain cannot be predicted
based on baseline uterine or leiomyoma volume is in
concordance with findings by Roth et  al.  (Roth et  al. 2000). Nor
the embolisation of both uterine arteries to complete stasis was
associated with the severity of pain.
Determinants of Uterine Ischaemia
Although most investigators have found normal perfusion
of the myometrium at mid- and long-term follow-up MRIs,
some case reports have described uterine necrosis after UAE
(Godfrey et  al. 2001, Torigian et al. 2005). Therefore, we also
evaluated possible determinants of the myometrial and
leiomyoma ischaemia. Our results imply that the infarction of
leiomyomas can be achieved by embolising to full stasis, which
often requires a considerable amount of microspheres. Indeed,
the volume of embolic agent correlated positively with the
leiomyoma ischaemia. On the other hand, embolisation of both
uterine arteries to complete stasis was not associated with the
severity of myometrial ischaemia. Further, Scheurig-Muenkler
et al. observed that transient uterine ischaemia regularly
occurred after UAE even with the use of a limited embolisation
technique (Scheurig-Muenkler et  al. 2010). It is notable that the
attempted endpoint of microsphere administration in our study
was near-stasis of the uterine artery, but in reality stasis was
complete in almost one-half of the arteries.
The apparently paradoxical finding that the use of a small
volume of embolisation agent and smaller uterine corpus were
associated with more severe myometrial ischaemia probably
reflects the difficulty in deciding the proper time point of
stopping microsphere administration, especially in the case of a
small uterus. In other words, because in small uteri also the
capacity of leiomyomas to intake microspheres is very limited,
even a small amount of embolic agent can cause myometrial
ischaemia. Thus, small uteri may be less suitable targets for
UAE.
These findings raise the question whether a more selective
embolisation technique or a technique with an earlier endpoint
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than “stasis or near stasis” could result in a therapeutic effect
with fewer side effects. The definition of endpoint based on DSA
is intrinsically subjective (Lewandowski et al. 2007). The contrast
enhanced ultrasound could be useful to detect the lack of
leiomyoma perfusion indicating the optimal amount of embolic
agent and the optimal endpoint of embolisation. In addition, a
combined CT and angiography suite  would  also  provide  more
objective means of verifying the lack of perfusion. In future,
intraprocedural MRI in interventional MRI suites might be a
feasible option for this without a radiation exposure. Currently,
however, effective postprocedural pain relief should be
available until the selection of the optimal endpoint of
embolisation, and the optimal type, size and amount of the
embolisation agent are clarified.
The repeatability of evaluation of ischaemia was good,
implying that the visual analysis of the severity and percentage
of the leiomyoma and myometrial ischaemia is a useful method
for clinical diagnostics. Pelage et al. used similar visual
analysing of percent ischaemia of leiomyomas at dynamic
sequence (Pelage et al. 2004).
We used VRS for assessing the postprocedural pain
intensity. It has proven to be as  valid, reliable and appropriate
for use in clinical practice as the Visual Analogue Scale and the
Numerical rating Scale (Williamson et  al. 2005). A review of
these three commonly used pain rating scales concluded that the
VRS is the least sensitive tool of the three, but it is easy to use,
while the VAS has the highest failure rate (Williamson et  al.
2005).
Limitations of Study III
Because the first postprocedural MRI after UAE was not
done at the time of maximum postprocedural pain, the study
provides only indirect evidence that myometrial ischaemia is
the main determinant of postprocedural pain. On the other
hand, it is clear that performing MRI at the time of severe
postprocedural pain is very challenging or even impossible.
Further, our analysis does not address other possible causes of
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postprocedural pain, such as ovarian and muscle ischaemia as a
result of inadvertent embolisation. Further, in the study
protocol, nondynamic delayed gadolinium- enhanced sequences
were obtained with single phase imaging 90 seconds after
contrast agent injection. The presence of non-enhancing tissue at
this time point indicates that there has not been detectable
perfusion in the earlier stages either.
6.4 VALUE OF QUANTATIVE MRI MEASUREMENTS IN
PREDICTING UTERUS AND LEIOMYOMA SIZE REDUCTION
AFTER UAE (STUDY IV)
According to the results of Study IV, the extent that UAE
will reduce the sizes of the uterus and dominant leiomyoma can
be predicted by simple analysis of preinterventional MRI
parameters. We selected the leiomyoma and uterine size as
outcome variables because they can be measured accurately by
MRI. Further, the limited size reduction after procedure has
been shown to be associated with clinical failure and recurrent
symptoms (Goodwin et  al. 1999, Lohle et  al. 2008, Pelage et  al.
2004). Further, Study I demonstrated that leiomyoma volume
and uterine dimensions in pre-MRI are associated with pressure
symptoms validating the feasibility of the results.
Leiomyoma-to-skeletal Muscle-ratio
In the study, the best predictor of leiomyoma and uterus size
reduction proved to be the leiomyoma-to-skeletal muscle SI-
ratio derived from T2-weighted images. Thus, leiomyoma size
reduction was highest in patients with high signal in T2-
weighted images. In three previous studies, the SI of
leiomyomas were assessed visually and compared with those of
skeletal muscle and myometrium (Burn et al. 2000, deSouza et al.
2002, Harman et  al. 2006): the authors also found that a
leiomyoma SI higher than that of skeletal muscle in T2 images
was predictive of a good response to UAE. Using numeric
values to characterize leiomyoma, instead of visual
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dichotomized variable, allowed us to identify continuum in the
relationship between SI and size reduction. Namely,
leiomyomas with SI three or four times higher than that found
in skeletal muscle underwent the highest size reductions
compared to leiomyomas only two times higher SI.
Histopathological basis for the low SI in T2- weighted
images has not been fully clarified. The results imply that a low
SI is associated with increased degeneration. However, this
notion  contrasts  with  findings  by  Yamashita  et  al.  who  found
that degenerated leiomyomas had higher signal in T2-weighted
images and that their response to gonadotropin-releasing
hormone analog was minimal (Yamashita et  al. 1993). In recent
studies with MRI-guided focused ultrasound, leiomyoma size
reduction was smallest in leiomyomas with high SI in T2-
weighted images as well (Funaki et al. 2007, Lenard et al. 2008).
Accordingly, it is possible that there are other factors than
degeneration (possibly cellularity) that explain these variable
results.
Image analysis was straightforward and consisted of two
ROIs drawn in a PACS system. Such measurement is feasible for
routine clinical work, because the same MRI sequencies can be
used to study uterus anatomy and size and location of the
leiomyoma.
T1 Time
Our finding that the long T1 time, i.e. low SI in T1-weighted
images, predicted the ability of UAE to reduce uterus and
leiomyoma sizes might be explained by a low concentration of
free proteins due to the presence of nondegenerated
leiomyomas. Similarly, three studies (Burn et al. 2000, Harman et
al. 2006, Jha et  al. 2000) found that leiomyomas with SI higher
than that of myometrium or skeletal muscle in T1-weighted
images were predictive of a poor response to UAE.
In the study, the imaging for T1 time was performed by
changing the inversion time manually; however, newer scanners
are able to measure T1 times automatically. Using the T1 time
for predictions provides advantages over using the leiomyoma-
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to-muscle T2 SI-ratio. First, the T1 time is measured only from
the leiomyoma, thus, the properties of fat between skeletal
muscle bundles do not influence the T1 time measurement. In
addition, modifications in sequence technology do not affect the
results of T1 time measurements because T1 time is an absolute
value. In contrast, T2 SI-ratios are relative and may be
influenced by equipment and technical imaging parameters.
Contrast Enhancement
In our study contrast enhancement was valuable in
identifying patients with 50% uterus size reductions.
Hypervascular leiomyomas have been shown to have a greater
reduction in vascularity than hypovascular leiomyomas (Jha et
al. 2000). Histologically, increased contrast enhancement is
associated with high cellularity, increased vessel density, and
low degeneration, measured as hyalinization (Yamashita et  al.
1993). Contrast enhancement could be a useful parameter in
leiomyomas that are hyperintense in T2 images due to
degeneration and show no enhancement due to necrosis.
Actually, nonenhancing leiomyoma has been used to preclude
UAE (Nikolaidis et al. 2005). The value of contrast enhancement
imaging in the present study was controversial. In Spearman
rank correlation analysis contrast enhancement was not
associated with leiomyoma size reduction. This result is
supported by two previous studies (Burn et al. 2000, deSouza et
al. 2002).
Limitations of Study IV
We did not correlate MRI findings with histopathological
characteristics. Further, multiphase or dynamic first-pass
perfusion imaging with absolute perfusion quantification could
possibly provide more comprehensive data of the value of
leiomyoma blood perfusions in the prediction of the UAE
results, as shown in patients treated with gonadotropin-
releasing hormone (Okuda et al. 2008).
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6.5 UTERINE ARTERY EMBOLISATION FOR LEIOMYOMAS IN
CURRENT CLINICAL PRACTICE
At the time of the start of this study, promising short-term
results of UAE in treating leiomyomas were reported. Recently,
as long as 5-year follow-up trials have been carried out (Lohle et
al. 2008, Spies et al. 2005c, van der Kooij et al. 2010). Our results
confirm the previous findings from the other randomised trials:
UAE is a valuable therapeutic option alternative for surgery in
women  with  symptomatic  leiomyomas.  UAE  is  no  longer
considered as an experimental treatment for leiomyomas. UAE
is currently accepted and considered a safe and effective
treatment for symptomatic women with uterine leiomyomas
(ACOG 2008, Joffre et al. 2004, Lohle et al. 2008, Pron et al. 2003a,
Pron et  al. 2003b, Pron et  al. 2003c, Pron et  al. 2005, Pron et  al.
2003d, Pron et  al. 2003e, Spies et  al. 2005c, Spies et  al. 2007,
Walker et al. 2006b, Walker et al. 2002, van der Kooij et al. 2010,
Watson et al. 2002, Volkers et  al. 2007). The minimally invasive
nature  of  the  procedure,  along  with  low  morbidity,  rapid
recovery, high success rates and the psychological advantage of
an organ-preserving treatment make UAE an attractive
alternative to surgical treatments.
Hysterectomy is the most common surgical treatment for
leiomyomas  in  Finland,  possibly  due  to  cultural  aspects  to
perform traditionally hysterectomy for the symptomatic women
who have completed childbearing. However, in recent years, the
rate of hysterectomies for leiomyomas has reduced. Recently,
the Finnish Office for Health Technology Assessment (Finnohta)
has made the recommendations for UAE in treating
symptomatic uterine leiomyomas. This systematic literature
search and evaluation by the group of Managed Uptake of
Medical Methods concluded that UAE is a safe, clinically
effective and cost-effective method as an alternative for
hysterectomy (Hippeläinen M 2011). However, despite the
growth of favourable outcome information, many gynecologists
do not routinely offer UAE as an alternative to hysterectomy. A
recent prospective study revealed that failure to fully disclose
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alternative minimally invasive treatment options may result in
patient dissatisfaction due to the fact that many patients do not
wish to have any surgery (Zurawin et al. 2010). In addition, in a
recent study of the clinical practise of UAE showed that
although UAE is widespread in Europe, the overall numbers of
UAE  procedures  seems  to  be  rather  low  (Voogt et  al. 2010).
Thus, the good collaborative relationship and open
communication between the gynecologist and interventional
radiologist facilitates leiomyoma treatment tailored according to
the carefully considered requests of individual patients.
A recent article by Goodwin and Spies reviews the clinical
recommendations for UAE (Goodwin et  al. 2009).  UAE  is  a
reasonable treatment option for most patients in whom UAE has
no contraindications. There are some important
contraindications to UAE, including pregnancy, pelvic cancer,
active infection, and some endometrial or adnexal abnormalities
requiring further treatment (Goodwin et  al. 2009). Thus, a
careful pre-embolisation evaluation both clinically and with
imaging together with appropriate technical expertise in
embolisation is important to effectively treat leiomyoma
patients. Although pregnancy is possible after embolisation,
existing data suggest better reproductive outcomes for
myomectomy in the first 2 years after UAE (Freed et  al. 2010,
Goodwin et al. 2009, Mara et al. 2008). Further, there is some data
that patients with very large leiomyomas and uteri may have
less satisfaction with the clinical results of UAE (Goodwin et al.
2009, Spies et al. 2002b).
Significant registry in this field, The Fibroid Registry for
Outcomes Data for Uterine Embolisation (FIBROID) was created
in 1999 (Goodwin et al. 2008, Myers et al. 2005, Spies et al. 2005b,
Worthington-Kirsch et  al. 2005). The results have demonstrated
that UAE results in a durable improvement in quality of life
when performed by an experienced interventional radiologist
(Goodwin et  al. 2008). Further, SIR has created standards of
practise for UAE including training, reporting, quality
assurance, and clinical care (Andrews et al. 2004, Andrews et al.
2009, Goodwin et al. 2003, Goodwin et al. 2001, Hovsepian et al.
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2004, Hovsepian et al. 2009, Spies et al. 2001c, Stokes et al. 2010).
A disease-specific symptom and health-related quality of life
questionnaire for leiomyomas, i.e. UFS-QOL, was developed as
part of the FIBROID Registry for the evaluating the severity of
symptoms  before  and  after  UAE  (Spies et  al. 2002c). UFS-QOL
would be a feasible tool particularly for comparing different
treatment options for leiomyomas. However, our study started
before publishing the questionnaire.
6.6 FUTURE PERSPECTIVES
The long-term (3-year) follow-up MRI and the clinical
success as well as the SF-36 forms of our prospective study
population should be analysed because UAE for leiomyomas
has not been applied widely in Finland. Comparison between
UAE and other uterine conserving procedures with longer
follow-up is needed.
It is an extremely important issue to clarify whether MRI has
value to select patients to UAE. There is no accurate
recommendation what kind leiomyomata uteri should or should
not be treated with UAE. In this study we concluded that we
can predict the extent that UAE will reduce the sizes of the
uterus and dominant leiomyoma at 6-month follow-up by
preinterventional MRI parameters. Thus, correlation study of
the 3-year clinical outcome with the preinterventional MRI
findings is warranted. Finally, the type and amount of embolic
agent continues to be a matter of debate.
Future studies should focus on analysing quantitatively the
absolute perfusion of leiomyomas and myometrium after UAE,
and try to find out if any perfusion parameters have prognostic
significance for long-term success, and if there will be any
negative long-term influences in perfusion of normal
myometrium tissue.
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6.7 ETHICAL ASPECTS
All study patients had symptoms that required treatment,
and the severity of  symptoms warranted consideration of
hysterectomy. The patients were provided written information
about the study (approved by ethics committee) as well as the
aims of the study. They also were given explanations about the
interventions, the sedation and anaesthesia needed. The risks,
benefits, and possible complications of UAE as a rather new
treatment were described. Further, they also were given the
opportunity to ask questions and time to consider participation.
The informed written consent was obtained from patients.
Before the initialising of this study, UAE was accepted and
widely utilized for post-partum hemorrhage, postoperative
bleeding, and arteriovenous malformations (Abbas et  al. 1994,
Korhonen et  al. 2010). Further, the initial results of UAE for
leiomyomas were promising and the rate of major complications
very low in previous studies.
All UAE interventions were performed by highly
experienced interventional radiologist, and hysterectomies were
performed as close of well-established daily practice as possible
by an experienced gynecologist. Concerning the postprocedural
pain after UAE and hysterectomy the patients were provided
with effective pain relief with intravenous opioids when
needed.
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7 Conclusions
1. In comparison with pressure symptoms, menorrhagia is
associated with a submucosal leiomyoma largely protruding
into the cavity, smaller uterine and leiomyoma size, and with
more intense contrast enhancement on MRI. The large
leiomyoma and uterine size contribute to increased urinary
frequency, whereas other mechanisms for urinary stress
incontinence and pain symptoms should be considered.
2. UAE is an effective and safe treatment option for women with
symptomatic leiomyomas in a mid-term follow-up. Concerning
with patient selection, UAE may be a preferable treatment over
hysterectomy especially for women with a feeling of pressure.
UAE is associated with faster recovery, but with an increased
number for secondary interventions. Even then, UAE is not
inferior to hysterectomy concerning patients’ satisfaction.
3. Postprocedural pain after UAE is a frequent adverse effect
and it is often severe. This pain is related to the
pathophysiological process of myometrial ischaemia caused by
effective embolisation and to the use a large amount of embolic
agent.
4. The extent that UAE will reduce the size of the uterus and the
dominant leiomyoma can be predicted by preinterventional
MRI parameters, i.e. the leiomyoma- to-skeletal muscle T2 SI-
ratio and T1 time of the dominant leiomyoma.
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Uterine artery embolisation (UAE), 
new treatment for uterine leiomyomas 
has been developed to substitute for 
major surgery. This randomised study 
comparing UAE and hysterectomy 
confirmed that UAE is a safe and 
effective treatment for symptomatic
leiomyomas. In addition, this thesis 
observed that post-UAE pain is often 
severe and is partly explained by 
myometrial ischaemia on 24-hour 
magnetic resonance imaging (MRI)
and large volume of embolic material. 
MRI measures can also be used to 
predict uterus and leiomyoma size 
reduction after UAE. Moreover, 
preinterventional MRI findings of
uterine leiomyomas give objective 
anatomical base for symptoms of 
leiomyomata patients.
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